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Abstract: Macroalgae, or seaweeds, are a rich source of components which may exert beneficial effects
on the mammalian gut microbiota through the enhancement of bacterial diversity and abundance.
An imbalance of gut bacteria has been linked to the development of disorders such as inflammatory
bowel disease, immunodeficiency, hypertension, type-2-diabetes, obesity, and cancer. This review
outlines current knowledge from in vitro and in vivo studies concerning the potential therapeutic
application of seaweed-derived polysaccharides, polyphenols and peptides to modulate the gut
microbiota through diet. Polysaccharides such as fucoidan, laminarin, alginate, ulvan and porphyran
are unique to seaweeds. Several studies have shown their potential to act as prebiotics and to
positively modulate the gut microbiota. Prebiotics enhance bacterial populations and often their
production of short chain fatty acids, which are the energy source for gastrointestinal epithelial
cells, provide protection against pathogens, influence immunomodulation, and induce apoptosis
of colon cancer cells. The oral bioaccessibility and bioavailability of seaweed components is also
discussed, including the advantages and limitations of static and dynamic in vitro gastrointestinal
models versus ex vivo and in vivo methods. Seaweed bioactives show potential for use in prevention
and, in some instances, treatment of human disease. However, it is also necessary to confirm these
potential, therapeutic effects in large-scale clinical trials. Where possible, we have cited information
concerning these trials.
Keywords: seaweed; prebiotics; gut microbiota; polysaccharides; polyphenols; peptides; colonic
fermentation; short chain fatty acids; bioaccessibility; simulated gastrointestinal and fermentation
digestion models
1. Introduction
Seaweed-derived components with potential to impact positively on diseases of the
body including hypertension [1], cancer [2], type-2-diabetes [3], obesity [4], oxidation [5],
inflammation [6] and other disorders have been evaluated in a number of studies to
date [7–15]. The pathogenesis of these disorders has been linked to the health of the gut mi-
crobiota [16]. The microorganisms that inhabit the human gastrointestinal tract—bacteria,
archaea, fungi, protozoa, and viruses—are collectively termed the gut microbiota [17].
The gut microbiota is established during infancy [18]. There is a broad variance amongst
individuals in microbiota composition because it is shaped by infant transitions such as
the gestational period, delivery method, weaning age, breast-feeding duration, or use of
formula milk [19]. The microbiota remains relatively stable throughout adulthood but is
affected by factors such as enterotype, antibiotic use, diet, lifestyle, genetic traits, and body
mass index [20]. Three enterotypes have been described in the human gut microbiome
based on variations in levels of the bacterial genera Bacteroides, Prevotella, and Ruminococ-
cus [21]. The gut microbiota is regarded as an endocrine organ that co-develops with the
host throughout its life. It exerts an effect on immunity, metabolism, neuroendocrine
responses, and synthesises vitamins, amino acids, and enzymes [22,23].
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The gut microbiota also aids in the absorption of dietary minerals and produces im-
portant short-chain fatty acids (SCFA) such as butyrate, propionate, and acetate. These
SCFA are the energy source for gastrointestinal epithelial cells, provide protection against
pathogens, influence intestinal mucosal immunity and barrier integrity, and induce apop-
tosis of colon cancer cells [24,25]. SCFA also regulate liver mitochondrial function, insulin
secretion, and induce the production of gut hormones γ-aminobutyric acid and serotonin
by interacting with their receptors on enteroendocrine cells [26,27]. An increase in the gut
bacterial population enhances the beneficial effects of the microbiota and increases SCFA
production [20]. An imbalance or decreased diversity of beneficial versus harmful bacterial
species in the gut microbiota is termed dysbiosis and is linked to several diseases [28–32].
Therefore, maintaining the health of the microbiota through diet or supplementary means
is thought beneficial to overall health [30]. Seaweed components may exert a beneficial
effect on gut health by acting as prebiotics [33,34]. The potential bioactivity of seaweed
components has been demonstrated previously in in vitro studies [35,36], however the
impact of gastrointestinal enzymatic digestion and colonic bacterial fermentation in vivo
must also be considered, since it may have an effect on the bioavailability of prebiotic and
other actives [37–39]. As a pharmacological concept, bioavailability is a measure of drug
absorption defined as the percentage of the drug that reaches blood circulation, measured
by a dose-response curve [40]. However, the evaluation of bioavailability in food-derived
extracts differs, since characteristic dose-response curves are not exhibited [41]. In addition,
the bioaccessibility of food-derived active compounds must be taken into account, i.e., the
accessible portion of the active compound released from the food or extract matrix during
digestion [42,43]. Although pharmacokinetic studies are required for the development of
prebiotics destined for human and animal use, such studies are not within the scope of
this review. The pharmacokinetics of seaweed-derived prebiotics in terms of absorption,
distribution, metabolism, and elimination has previously been documented in animal
studies after oral administration [44–48] and topical application [49], and recently reviewed
by Corino et al. [50] and Shikov et al. [51].
This review outlines current knowledge on the potential beneficial effect of seaweed
polysaccharides, polyphenols, and peptides on the gut microbiota and the impact of gas-
trointestinal digestion and colonic fermentation on their bioaccessibility. The advantages
and limitations of static and dynamic gastrointestinal models, and in vitro, ex vivo, and
in vivo bioaccessibility and bioavailability assessment methods concerning seaweed bioac-
tives and their prebiotic and potential beneficial health effects are discussed.
2. Discussion
Seaweed components that have the potential to exert beneficial effects on the gut by
modulating the abundance and diversity of bacterial populations in the gut microbiota
include polysaccharides, polyphenols, and peptides. Their structure, function, and studies
regarding their potential impact on the gut are considered in this review. Despite the
positive results reported from cited studies concerning in vitro and animal work, more
research is required in human dietary intervention studies, with health-related end points,
to determine prebiotic potential.
2.1. Polysaccharides
Polysaccharides, or carbohydrates, are repeating units of monosaccharides linked
by glycosidic bonds found in all plants, fungi, and algae. They are considered primary
metabolites with structural and energy storage functions [52]. The majority of seaweed
polysaccharides are composed of water-soluble and -insoluble fibre [53,54]. The total
fibre content of seaweed varies between species and has been reported to range from
35–62% in brown, to 10–57% in red and 29–67% in green (DW) [55–59]. The principal
fibres in brown seaweeds are fucoidan, laminarin, and alginate; porphyran, carrageenan,
hypnean and floridean starch in red; and ulvan, sulphated-rhamnans, -arabinogalactans
and -mannans in green [60,61]. Humans do not produce the endogenous enzymes in the
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upper gastrointestinal tract required to degrade dietary fibre to monosaccharides. However,
fibre is an excellent food substrate, or prebiotic, for human gut bacteria [62,63]. Prebiotics
are food components that are indigestible in the small intestine but can be metabolised
by microorganisms in the large intestine, modulating their composition and/or activity,
thus conferring a beneficial physiological effect on the host [64]. Many species of gut
bacteria produce endogenous carbohydrate-degrading enzymes, such as β-glucanase and
β-glucosidase, capable of hydrolysing the glycosidic linkages of polysaccharides [65–68].
Several polysaccharides within seaweed that are indigestible in the upper gastrointestinal
tract are thought to exert bioactive effects including glycaemic control [69] and the promo-
tion of gut microbial- and immune-modulation by acting as prebiotics in in vitro and in vivo
studies [70,71]. The bioactivity of polysaccharide fractions is influenced by a number of
factors such as chemical structure, molecular weight (MW), solubility, extraction method,
seaweed genus and seasonal variation [72,73]. The principal polysaccharides of brown,
red, and green seaweeds are detailed below.
2.1.1. Fucoidans
Three polysaccharides—fucoidans, laminarin and alginate—occur within brown sea-
weeds, each of which have differing structures and functions [74]. Fucoidans comprise
5–20% (DW) of the entire seaweed thallus [75,76]. They are water-soluble sulphated-
polysaccharides composed of repeating fucose and sulphate groups, and may also contain
galactose, mannose, xylose, rhamnose, arabinose, glucose, acetyl groups, or glucuronic
acid [77]. The molecular weight of fucoidans varies from 7 to 2300 kDa [11]. Fucoidans
provide structure for the outer cell wall and a hydrophilic coating to prevent desiccation of
the seaweed during low tide. They also play a role in adapting to osmotic stress caused
by changes in salinity as their sulphate groups can bind to cations such as sodium, potas-
sium, magnesium, and calcium [78,79]. Fucoidans have previously been shown in in vitro
studies to have potential for use as anticancer [80], antiviral [81], antioxidant [77], and
anti-inflammatory [82] agents; and in vivo as anticoagulants (human trial) [83], anticancer
(human trial) [84], antitumour (mouse model) [85], antihyperglycaemic, and antihyperlipi-
daemic agents (mouse model) [86]. However, the oral bioavailability of fucoidan can be low
due its highly polar nature and limited ability to pass through intestinal epithelial cells [68].
In recent years, the prebiotic status of fucoidan has been recognised in vitro [82,87] and in
human [88] and animal [89–92] gastrointestinal studies.
2.1.2. Laminarin
The energy storage polysaccharide of brown seaweeds is laminarin, composed of
β(1–3)-linked glucose units with β(1–6)-branches [93]. It occurs within the chloroplasts
in micro-compartments called pyrenoids [94]. Laminarin is water-soluble, though in-
creased branching of the molecule requires colder temperatures for solubility. It comprises
3–35% of brown seaweed dry mass and is most prevalent in Laminaria species [95]. It is
a small polysaccharide with a molecular weight of approximately 5 kDa [96]. Laminarin
has shown efficacy in in vitro studies carried out previously and has potential for use
as an anticancer [97], antimetastatic [98], antioxidant [99] and immunostimulatory [100]
agent [97,99,100]; and in vivo as an immunomodulatory agent [101] and prebiotic to modu-
late dysbiosis (animal models) [102–105].
2.1.3. Alginate
Alginate comprises up to 45% of brown seaweed dry mass [106], occurring in the
cell walls as salts of alginic acid bound to sodium, calcium or magnesium ions [107]. It
is a water-soluble linear polysaccharide composed of (1–4)-linked β-D-mannuronate and
α-L-guluronate residues [108]. Molecular weight ranges from 20 to 350 kDa [109,110]. It is
the most abundant polysaccharide in brown seaweed and imparts flexibility to the thallus
to withstand the force of the ocean. Alginate is a phycocolloid that can bind up to 20 times
its own mass with water, making it very useful for food and industrial applications [111].
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The prebiotic effect of alginate on gut microbiota was demonstrated previously in vitro by
Bai et al. [112] and Li et al. [113]; and in a human study by Mizuno et al. [114]. Bai et al.
fermented seaweed-derived alginates in vitro and observed that the alginates were de-
graded by human-derived gut bacteria, producing a significant (p < 0.05) increase in SCFA
compared to a starch control, and suggested that further investigations of the prebiotic
effects of alginate are warranted. Li et al. also fermented seaweed-derived alginates with
human faecal bacteria in vitro and found a significant (p < 0.05) increase in total SCFA
in the alginate sample (78.6 ± 5.9 mM) compared to the control (62.5 ± 5.1 mM). The
bacterial Richness index in the alginate ferment (15.83 ± 2.3) was also significantly greater
(p < 0.05) than that of the control (12.67 ± 2.88). The authors propounded that alginate
may be capable of sustaining the growth of human gut bacteria, and recommended further
study to evaluate the potential impact that alginate food additives may exert on host health.
The in vivo study by Mizuno et al. was an interventional study of 11 elderly patients who
required enteral feeding. After 4 weeks of receiving the alginate formula (equivalent to
14.52 g fibre/day) there was a significant increase (p = 0.039) in Clostridium cluster XI
bacteria compared with the baseline. However, there was no increase in Bifidobacterium,
Lactobacillales, or Bacteroides. The patients’ stool form improved (p = 0.044) (Bristol Stool
Scale), as did mean blood concentrations of total SCFA (p = 0.042), acetic acid (p = 0.042),
propionic acid (p = 0.027), serum albumin (p = 0.039), total cholesterol (p = 0.002), and
cholinesterase (p = 0.034). The alginate did not induce any significant changes in stool
frequency, body weight, or arm circumference. The authors suggested that the alginate-
containing liquid formula may potentially exert a beneficial prebiotic effect on intestinal
function through increased production of SCFA. However, the limitations of the study were
noted due to the small sample size and single-center study design. In order to validate the
findings, the authors recommend a larger, multicenter study.
Alginate may also be useful in the prevention of metabolic syndrome syndrome [115].
It can increase the viscosity of gastric contents, reducing postprandial glucose absorption
and insulin response [116], and may thereby impact on hyperlipidaemia and hyperten-
sion [1,117].
2.1.4. Carrageenans
Within red seaweeds, carrageenans and porphyran are the prevalent polysaccharides.
The family of linear, sulphated polysaccharides, carrageenans, occur as a structural compo-
nent of the extracellular matrix [118]. Of the 15 different carrageenan forms, iota (ι), kappa
(κ) and lambda (λ) are the most widely used as phycocolloids in the food industry [119] and
as a vegan alternative to beef gelatin in pharmaceutical capsules [120]. κ and ι-carrageenan
are composed of alternating D-galactose and 3,6-anhydro-galactose units with varying
numbers of sulphate groups, while λ-carrageenan lacks 3,6-anhydro-galactose and has
alternating α-1,3 and β-1,4 inter-galactose bonds [121]. Average molecular weight ranges
from 453 to 652 kDa [122]. All forms of carrageenan are soluble in water above their gel-
melting temperatures (40–70◦ C). In cold water, only λ-carrageenan and the sodium salts of
κ and ι-carrageenan are soluble [93]. ι-carrageenan was shown to reverse the symptoms
of metabolic syndrome in a rat model by significantly decreasing systolic blood pressure,
body mass (BM), abdominal and liver fat, and total cholesterol, while also beneficially mod-
ulating the gut microbiota [123]. As potential antitumour agents, κ/ι hybrid carrageenans
have shown activity in vitro against colorectal cancer stem cell-enriched tumourspheres [2].
However, simulated gastrointestinal studies have found that κ-carrageenan can be both
beneficial and harmful by increasing or decreasing markers of inflammation and the growth
of beneficial gut bacteria and SCFA. This is dependent on the degree of polymerisation of
the carrageenan [124].
2.1.5. Porphyran
Porphyran is a sulphated polysaccharide that occurs in red seaweed, within the genus
Porphyra, and comprises approximately 11–21% of the seaweed dry mass [125]. It is
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composed of repeating units of galactose and 3,6-anhydrogalactose, with alternating units
of galactose-6-sulphate and 6-O-methyl-galactose [126]. Average molecular weight ranges
from 14 to 201 kDa [127,128]. Porphyran is soluble in hot water and has similar structural
functions to carrageenan, though its higher viscosity limits its pharmaceutical applica-
tions [128,129]. Porphyran has shown potential antioxidant and anti-inflammatory effects
in cell studies using RAW264.7 cell line [125] and was found to promote cell migration
and proliferation in intestinal epithelial cells [127]. It also has antitumor activity against
HeLa cells [130], HT-29 colon cancer cells and AGS gastric cancer cells [131]. As a prebiotic,
porphyran was previously found to increase beneficial gut bacteria and SCFA production
in vitro in simulated digestion studies [126,132,133] and in animal studies as whole red
seaweed [134–136].
2.1.6. Ulvans
Green seaweeds are dominated by the ulvans, which account for 38–54% of the
thallus dry mass [137]. Ulvans are water-soluble, gelling polysaccharides composed of
repeating units of sulphated L-rhamnose, D-xylose, D-glucuronic acid and its epimer L-
iduronic acid [138]. Molecular weights range widely from 1 to 2000 kDa depending upon
the degree of sulphation [139]. Ulvans have demonstrated potential anticoagulant [140],
antibacterial [141], antiviral [142], and immunoregulatory (porcine intestinal epithelial
cells) [143] activities in vitro. They have also shown potential for the use as prebiotics in
animal studies [144] and in vitro [132,145,146].
2.2. Gastrointestinal Digestion Studies with Seaweed Polysaccharides
A number of recent studies have used simulated in vitro gastrointestinal digestion
or in vivo clinical trials to investigate the effect of polysaccharides on beneficial bacte-
rial populations and their metabolites. Table 1 summarises the polysaccharide fraction
used in each study and its impact on gut bacteria. Further characterisation and in vivo
animal and human dietary intervention studies are required to confirm any potential
therapeutic benefits.
Table 1. The impact of polysaccharides on gut bacteria.
Polysaccharide Seaweed Extraction Method Study Type Statistically Significant Effects Ref.
* (i) Crude
polysaccharide-rich
extract (>1 kDa) (CE)
(ii) Depolymerised
crude extract (>1 kDa)
(DE)
L. digitata








After 24 h fermentation, compared to
cellulose control:
• CE increased relative abundance
of Porphyromonadaceae (p = 0.043),
Lachnospiraceae (p = 0.015) and
Dialister (p = 0.005); and reduced
Fibrobacteraceae (p = 0.026)
Streptococcaceae (p = 0.025),
Ruminococcus, (p = 0.027)
Streptococcus (p = 0.022) and
Fibrobacter (p = 0.026).
• DE increased Parabacteroides
(p = 0.017) Lachnospiraceae
(p = 0.039), Dialister (p = 0.008)
and reduced Alcaligenaceae (a
Proteobacterium) (p = 0.030) and
Peptostreptococcaceae Incertae Sedis
(p = 0.027).
CE and DE increased total SCFA, acetic,
propionic, and butyric acid (all p < 0.05)
after 10, 24, 36, and 48 h.
Ratio of propionate to acetate
beneficially reduced by CE and DE (both
p < 0.05) after 24, 36, and 48 h.
[147]
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Table 1. Cont.
Polysaccharide Seaweed Extraction Method Study Type Statistically Significant Effects Ref.






After 24 h fermentation, growth of
bacterial genera compared to
fructooligosaccharide (FOS) control:
Porphyran increased Lactobacilli (10.7%,
p < 0.05).
Ulvan increased Bacteroides (6.7%,
p < 0.05).
Laminarin increased Bifidobacteria
(8.3%, p < 0.05) and Bacteroides (13.8%,
p < 0.05).
Negative results: no significant increase
at 24 h in total SCFA, butyrate, lactate or
acetate by laminarin, ulvan or porpyran
compared to FOS.
[132]
* (i) Crude extract
fraction (CF)
(ii) Low MW fraction
(LPF)













Increases (log10 cells/mL) after 24 h
fermentation (all p < 0.05 compared to
controls):
Mar. Drugs 2021, 19, x FOR PEER REVIEW 7 of 56  
 




 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
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 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production aft r 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Bacteroidetes (CF 7.36 ± 0.03,
LPF 7.21 ± 0.05 and HPF
7.28 ± 0.04) grea r than cellulose
(6.40 ± 0.05).
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(iii) Water and 
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precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
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[148] 
Faecalibacterium prausnitzii (CF
6.34 ± 0.05, LPF 6.42 ± 0.08)
greater than in lin (6.17 ± 0.04)
and cellulose (6.07 ± 0.06).
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in any other bacterial populations. 
[148] 
Clostridium coccoides (CF
8.29 ± 0.03, LPF 8.56 ± 0.06)
greater than in lin (7.57 ± 0.06)
and cellulose (7.40 ± 0.05)
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) gr ater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6. 6 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin p sitive control. HPF (68.9 μmol/mL) greater than 
llulose 39.7 μmol/mL) but ~20% lower than inulin. 
 Ac tic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
co pared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide cidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifid bact ria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se fermented control) to .55  .08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no signific nt increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Escherichia coli (CF 7.16 ± 0.04,
LPF 7.31 ± 0.05 and HPF
6.96 ± 0.04) grea r than cellulose
(6.81± 0 03)
Mar. Drugs 2021, 19, x FOR PEER REVIEW 7 of 56  
 




 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) gr ater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6. 6 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 Total SCFA in F (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin p sitive control. HPF (68.9 μmol/mL) greater than 
llulose 39.7 μmol/mL) but ~20% lower than inulin. 
 Ac tic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic aci  CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
R tio f Firmicutes to Bacteroid tes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
co pared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide cidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifid bact ria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se fermented control) to .55  .08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no signific nt increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Bifidobacteria (LPF 7.11 ± 0.12)
greater than cellulose
(6.34 ± 0.06)
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cell lose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, PF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 ifidobacteri  (LPF 7.11 ± 0.12) greater tha  cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cell l se (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 Total SCFA in  (97.3 ol/ ), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (4 .8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to ellulose 
(1.22 ± 0.004)  Ratio of propi nic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 ( nuli ) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (H ) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h p st fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cell lose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Lactobacilli (LPF 6.56 ± 0.05)
greater than inulin (6.07 ± 0.05)
and cellulos (5.11 ± 0.06)
SCFA production after 24 h (all p < 0.05):
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 Clostridium cocc id s (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than
inulin (7.57 ± 0. 6  cellu ose (7.40 ± 0.05)
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) gr ater than cellulose (6.81± 0.03) 
Bifi obacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
Lactobacilli (LPF 6. 6 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0. 6) 
SCFA production after 24 h (all p < 0.05): 
 T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
th n inulin p sitive control. HPF (68.9 μmol/mL) greater tha  
llulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Ac tic acid HPF (40.8 μmol/mL) > cellulose 
 Propi ic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) nd LPF (1.18 ± 0. 06) compared to cellulose 
1.22 ± 0.004). Ratio o  propionic acid to acetic acid beneficially 
r d ced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
c pared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cell l se). 
* (i) Low  
polysaccharide (LMW) 
(primarily laminarin) 
(ii) High MW 
polysaccharide cidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 












(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
) LMW increased Bifid bact ria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se fermented control) to .55  .08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (ce lulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no signific nt increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Total SCFA in CF (97.3
µmol/mL), LPF (89.0 µmol/mL)
greater than in lin positive
control. HPF (68.9 µmol/mL)
great r than cellulose
(39.7 µmol/mL) but ~20% l wer
than inulin.
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 Clos ridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellu ose (7.40 ± 0.05)
 Escherichia coli (CF .16 ± 0.04, PF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) gr ater th  cel ul se (6.81± 0.03) 
Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
Lactobacilli (LPF 6. 6 ± 0.05) greater than inulin (6.07 ± 0.05) and 
ll l se (5.11 ± 0. 6) 
SCFA production after 24 h (all p < 0.05): 
 T tal SCFA in  (97.3 ol/ ), LPF (89.0 μmol/mL) gre ter 
than inulin p sitive control. HPF (68.9 μmol/mL) greater than 
llulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Ac tic cid HPF (40.8 μmol/mL) > cellulose 
 Propionic aci  CF (54.6 μmol/mL) > inulin and cellul se 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicut s to Ba teroidetes beneficially lowered: HPF (1.08 ± 
. 08), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 
* (i  Low  
l i  (LMW) 
(primarily laminarin) 
 
(ii) High MW 
polysaccharide cidic water 
extract (H ) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 
polysaccharide water and 
ethanol precipitate 
E. radiata 









(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h p st f rmentation (all differences p < 0.05): 
) LMW incre sed Bifid bact ria from 5.51 ± 0.15 log10 cells/mL (in 
cell l se fermented control) to .55  .08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (ce lulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no signific nt increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Acetic acid HPF (40.8 µmol/mL
> cellulose
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0. 6) greater than 
inulin (7.57 ± 0.06) and cellulose ( .40 ± 0.05) 
 Escherichia coli (  7.1  ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) gre ter than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± .06) 
 Lactobacilli (  6.56 ± 0.05) gr ater tha  i ulin (6.07 ± 0.05) and 
cellu ose . 1 ± .06) 
SCFA production after 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/ L), LPF (89.0 μ ol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulo e (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/ L) > cellulose 
 Pr pionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes benefi ially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.0 6) compared to cellulose 
(1.22 ± 0. 04). Ratio of propionic acid t  acetic acid ben ficiall  
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 
* (i) Low MW 
polysaccharide (LMW) 
(prim rily laminarin) 
 
 
(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post ferme tation (all differences p < 0. 5): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose f rme ted contr l) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Propion c acid CF
(54.6 µmol/mL) > inulin and
cellulose
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 Clostridium cocc id s (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than
inulin (7.57 ± 0. 6   cellulose (7.40 ± 0.05) 
 Es herich a coli (  7.1  ± .04, LPF 7.31 ± 0.05 a d HPF 6 96 ± 
0.04) gr ater tha  cellulose (6.81± 0.03) 
 Bifi obacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± .06) 
Lactobacilli (LPF 6. 6 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than nulin p sitive control. HPF (68.9 μmol/mL) great r tha  
llulose (39.7 μ l/ L) but ~20% lower than inulin. 
 Ac tic id HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellul se 
 Butyric acid LPF (17.3 μmol/mL) > inul n n cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0. 0 ) a d LPF (1.18 ± 0.0 6) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
c mpared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cell l se). 
* (i) Low  
polysaccharide (LMW) 
prim rily laminarin) 
 
(ii) High MW 
polysaccharide cidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 












(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post ferme tation (all differences p < 0.05): 
(i) LMW increased Bifid bact ria from 5.51 ± .15 log10 cells/mL (in 
cellul se f rmented control) to .55  .08 log10 cells/mL; Lac obacillus
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no signific nt increase by LMW on p pulations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoid s from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Butyric acid LPF (17.3 µm l/mL)
> inulin and c llulose
Ratio of Firmicutes to Bacter idetes
be eficially lowered: HPF (1.08 ± 0.008),
CF ( .14 ± 0.001) and LPF (1.18 ± 0.006)
compared to cellulose (1.22 ± 0.004).
Ratio of propionic acid to acetic acid
beneficially reduced: 0.47 ± 0.04 (CF),
0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF)
compared to 4.08 ± 0.18 (in lin) and
5.73 ± 0.13 (cellulose).
[10]
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Table 1. Cont.
Polysaccharide Seaweed Extraction Method Study Type Statistically Significant Effects Ref.















(ii) Acidic water (pH 4.5)




24 h post fermentation (all differences
p < 0.05):
(i) LMW increased Bifidobacteria from
5.51 ± 0.15 log10 cells/mL (in cellulose
fermented control) to 6.55 ± 0.08 log10
cells/mL; Lactobacillus from 4.73 ± 0.13
(cellulose) to 5.28 ± 0.19 log10 cells/mL
and Bacteroidetes from 5.09 ± 0.06
(cellulose) to 6.02 ± 0.09 log10 cells/mL.
Negative results: no significant increase
by LMW on populations of F. prausnitzii,
Clostridium leptum, Ruminococcus bromii,
E. coli or Enterococcus.
(ii) HMW increased C. coccoides from
5.74 ± 0.75 (cellulose) to 7.07 ± 0.04
log10 cells/mL, E. coli from 6.09 ± 0.41
(cellulose) to 7.52 ± 0.07 log10 cells/mL
and Enterococcus from 5.02 ± 0.31
(cellulose) to 6.63 ± 0.11 log10 cells/mL.
Negative results: no significant increase
by HMW in any other bacterial
populations.
(iii) HMWW increased E. coli from
6.09 ± 0.41 (cellulose) to 7.01 ± 0.17
log10 cells/mL and Enterococcus from
5.02 ± 0.31 (cellulose) to 5.80 ± 0.33
log10 cells/mL.
HMWW also had a negative effect on
several bacterial
populations—Bifidobacteria reduced
from 5.51 ± 0.15 (cellulose) to
3.21 ± 0.61 log10 cells/mL, Bacteroidetes
from 5.09 ± 0.06 (cellulose) to
4.08 ± 0.12 log10 cells/mL, Lactobacillus
4.73 ± 0.13 log10 cells/mL (cellulose) to
not detected (ND), C. coccoides from
5.74 ± 0.75 log10 cells/mL (cellulose) to
ND, C. leptum from 6.23 ± 0.28 log10
cells/mL (cellulose) to ND and R. bromii
from 6.20 ± 0.06 (cellulose) to
4.87 ± 0.29 log10 cells/mL.
SCFA increases in seaweed ferments vs.
cellulose control after 24 h (all p < 0.05):
1. LMW
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production afte  24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulos  (39.7 μmol/mL) but ~20% lower than inulin. 
 A etic cid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Total SCFA 63.42 ± 1.76 vs.
18.59 ± 0.14 µmol/mL
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA roduction after 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellul se (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Acetic acid 22.81 ± 0.91 vs.
9.09 ± 0.07 µmol/mL
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 Clostri ium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA produ tion after 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Propionic acid 29.61 ± 2.60 vs.
3.24 ± 0.04 µmol/mL
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inu in (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
FA production a ter 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ra io f propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF)
ompar d to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Butyric acid 9.22 ± 1.38 vs.
2.02 ± 0 03 µmol/mL
2. HMW
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and ce ulose (7.40 ± 0.05) 
Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0 5 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
Lactob lli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellul se (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 T al SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater
than inulin positive control. HPF (68.9 μm l/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/m ) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) nd 5.73 ± 0.13 (ce lulose). 
* (i) Low  
l sacc ari e LMW) 
(primarily laminarin) 
) High  
acidic water 
xtract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 











(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increase  Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se ferm nt control) to 6.55 ± 0 08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellul se) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative r sults: no si nificant increase by LMW on populations of F. 
prausnitzii, Clostrid um le tum, R minococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Total SCFA 62.86 ± 0.20 vs.
18.59 ± 0.14 µmol/mL
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and ce ulose (7.40 ± 0.05) 
Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0 5 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
Lactob lli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellul se (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater
than inulin positive control. HPF (68.9 μm l/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/m ) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 
* (i) Low  
l sacc ari e LMW) 
(primarily laminarin) 
) High  
acidic water 
xtract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 











(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increase  Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se ferm nt control) to 6.55 ± 0 08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellul se) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative r sults: no si nificant increase by LMW on populations of F. 
prausnitzii, Clostrid um le tum, R minococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Acetic acid 20.59 ± 0.21 vs.
9.09 ± 0.07 µmol/mL
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and ce ulose (7.40 ± 0.05) 
Esch richi  coli (CF 7.16 ± 0.04, LPF 7.31 ± 0 5 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
Lactob lli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellul se (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater
than inulin positive control. HPF (68.9 μm l/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/m ) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.00 ) compared to cellulose 
(1.22 ± 0.004). Ratio of propio ic acid to acetic acid benefici lly 
red ced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 
* (i) Low  
l sacc ari e LMW) 
(primarily laminarin) 
) High  
acidic water 
xtract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 











(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increase  Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se ferm nt control) to 6.55 ± 0 08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellul se) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative r sults: no si nificant increase by LMW on populations of F. 
prausnitzii, Clostrid um le tum, R minococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Propionic acid 36.79 ± 0.57 vs.
36.79 ± 0.57 µmol/mL
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and ce ulose (7.40 ± 0.05) 
Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0 5 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria ( PF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
Lactob lli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellul se (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater
than inulin positive control. HPF (68.9 μm l/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic aci  CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
R tio f Firmicutes to Bacteroid tes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.00 ) compared to cellulose 
(1.22 ± 0.004). Ra io f propio ic ac d to acetic acid benef ci lly 
red ced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF)
ompar d to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 
* (i) Low M  
polysaccharide LMW) 
(primarily laminarin) 
) High  
acidic water 
xtract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 











(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose ferm nt control) to 6.55 ± 0 08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellul se) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative r sults: no si nificant increase by LMW on populations of F. 
prausnitzii, Clostrid um le tum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Butyric acid 4.27 ± 0.48 vs.
2.02 ± 0 03 µmol/mL
3. HMWW
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 Cl s ridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and ce ulose (7.40 ± 0.05) 
Escher chia coli (CF .16 ± 0.04, PF 7.31 ± 0 5 and HPF 6.96 ± 
0.04) greater than cellul se (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater th n cellulose (6.34 ± 0.06) 
Lactob lli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
llul se (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 T al SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater
than inulin positive control. HPF (68.9 μm l/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/m ) > inulin and cellulo e 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially owered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.00 ) compared to ulose 
(1.22 ± 0.004). Ratio of propio ic a id to acetic acid benefici lly 
red ced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) nd 5.73 ± 0.13 (ce lulose). 
* (  Low  
LMW) 
(primarily lam narin) 
) High  
acidic water 
xtract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 
polysaccharide water and 
ethanol precipitate 
E. radiata 
i) E zymatic 
(cellulase) 
 





(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post f rmentation (all differences p < 0.05): 
(i) LMW incre se  Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se ferm nt control) to 6.55 ± 0 08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellul se) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative r sults: no si nificant increase by LMW on populations of F. 
prausnitzii, Clostrid um le tum, R minococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Total SCFA 50.70 ± 1.10 vs.
18.59 ± 0.14 µmol/mL
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 Cl s ridiu  coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and ce ulose (7.40 ± 0.05) 
Escherich a coli (CF .16 ± 0.04, PF 7.31 ± 0 5 and HPF 6.96 ± 
0.04) greater than cellul se (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater th n cellulose (6.34 ± 0.06) 
Lactob lli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
llul se (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater
than inulin positive control. HPF (68.9 μm l/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/m ) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 
* (  Low  
LMW) 
(primarily lam narin) 
) High  
acidic water 
xtract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 
polysaccharide water and 
ethanol precipitate 
E. radiata 
i) E zymatic 
(cellulase) 
 





(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post f rmentation (all differences p < 0.05): 
(i) LMW incre se  Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se ferm nt control) to 6.55 ± 0 08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellul se) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative r sults: no si nificant increase by LMW on populations of F. 
prausnitzii, Clostrid um le tum, R minococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Acetic acid 27.05 ± 0.58 vs.
9.09 ± 0.07 µmol/mL
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 Cl s ridiu  coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and ce ulose (7.40 ± 0.05) 
Escherichia coli (CF .16 ± 0.04, PF 7.31 ± 0 5 and HPF 6.96 ± 
0.04) greater than cellul se (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater th n cellulose (6.34 ± 0.06) 
Lac ob lli (LPF 6.56 ± 0.05) gr ater than inulin (6.07 ± 0.05) and 
llul se (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μ ol/mL) greater
than inulin positive control. HPF (68.9 μm l/mL) greater than 
cellulo e (39.7 μmol/mL) but ~20% lower than inulin. 
 Acet c acid HPF (40.8 μmol/ L) > cellulose 
 Pr pionic acid CF (54.6 μmol/m ) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cel ulose 
Ratio of Firmicutes to Bacteroidetes benefi ia ly lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.0 ) compared to cellulose 
(1.22 ± 0. 04). Ratio of propio ic acid t  acet c acid ben fici ll  
red ced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 
* (  Low  
LMW) 
(primarily lam narin) 
) High  
acidic water 
xtract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 
polysaccharide water and 
ethanol precipitate 
E. radiata 
i) E zymatic 
(cellulase) 
 





(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post f rmentation (all differences p < 0.05): 
(i) LMW incre se  Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se ferm nt control) to 6.55 ± 0 08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellul se) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative r sults: no si nificant increase by LMW on populations of F. 
prausnitzii, Clostrid um le tum, R minococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Propionic acid 18.20 ± 0.38 vs.
3.24 ± 0.04 µmol/mL
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 Cl stridiu  coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and ce ulose (7.40 ± 0.05) 
Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0 5 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteri ( PF 7.11 ± 0.12) greater th n cellulose (6.34 ± 0.06) 
Lac ob lli (LPF 6.56 ± 0.05) gr ater than inulin (6.07 ± 0.05) and 
cellul se (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μ ol/mL) greater
than inulin positive control. HPF (68.9 μm l/mL) greater than 
cellulo e (39.7 μ ol/mL) but ~20% lower than inulin. 
 Acet c acid HPF (40.8 μmol/ L) > cellulose 
 Pr pionic cid F (54.6 μmol/ L) > inulin and cellulose 
 Butyric acid LPF (17.3 μ ol/mL) > inulin and cel ulose 
R tio f Firmicutes to Bacteroid tes benefi ia ly lowered: HPF (1.08 ± 
.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.0 ) compared to cellulose 
(1.22 ± 0. 04). Ra io f propio ic ac d t acet c acid ben f ci ll  
red ced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF)
ompar d to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 
* (i) Low M  
polysaccharide LMW) 
(primarily laminarin) 
) High  
acidic water 
xtract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 











(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post f rmentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose ferm nt control) to 6.55 ± 0 08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellul se) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative r sults: no si nificant increase by LMW on populations of F. 
prausnitzii, Clostrid um le tum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
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Table 1. Cont.









(ii) Whole dried E.
radiata
In vivo trial with healthy
Sprague-Dawley rats
(7 d, 5% PF or 5% WS
added to feed)
After 7 days supplementation (all
differences p < 0.05):
Reduction in potentially pathogenic
Enterococci in WS group (6.04 ± 0.09
log10 cells/mL) vs. control (5.59 ± 0.08
log10 cells/mL)
Increase in butyrate-producing F.
prausnitzii in PF group (5.32 ± 0.11 log10
cells/mL) vs. control (4.87 ± 0.11 log10
cells/mL)
2-fold increase in caecal digesta mass
1.36 ± 0.17 (PF) vs. 0.60 ± 0.06 g/100 g
BM (control)
Putrefactive microbial products reduced
(all values µg/g caecal digesta):
• phenol in WS (0.36 ± 0.03) and PF
(0.49 ± 0.02) vs. control
(2.91 ± 0.70)
• p-cresol in WS (0.47 ± 0.05)
SCFA increase in WS (213.25 ± 14.40
µmol) and PF (208.59 ± 23.32 µmol) vs.
control (159.96 ± 13.10 µmol)Negative
results:
– No significant p-cresol decrease
in PF fed rats (19.34 ± 5.14) vs.
















(i, ii, and iii) Ethanol
followed by acidic
water (0.01 M HCl)
(iv) Cellulase, acetate
buffer (pH 4.5)




added at 0.1%, 0.3% and
0.5% (w/v)
All differences p < 0.05 compared to
non-supplemented control medium:
Increase in L. delbrueckii ssp. bulgaricus
by CCE, MAE, UAE and EAE at 0.1%,
0.3% and 0.5%.
Increase (24.5%) in L. casei only by MAE
at 0.5% inclusion.
Negative results:
– No significant increase in L. casei










M HCl) and ethanol
precipitation
Simulated in vitro saliva,
gastric, small intestinal
and colonic digestion
After 24 h, all differences p < 0.05
compared to inulin control:
Increase in Bacteroides, Parabacteroides,
Megamonas and Veillonella.
Increase in total SCFA
(22.17 ± 0.82 mmol/L) vs. control
(16.17 mmol/L ± 0.39).
Negative results:
– No significant increase in
butyrate, lactate, iso-butyrate,





(SJP) (138 kDa) (Fu-
cose:galactose:glucuronic
acid:mannose, molar










by 0.6 M HCl
Simulated in vitro
colonic digestion
After 24 h, all differences p < 0.05
compared to FOS control
• Increase in beneficial
Bacteroidetes and decrease in
Proteobacteria (SJP and SJO).
• Increased ratio of Bacteroidetes to
Firmicutes (SJP and SJO).
[91]
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In vivo trial with
lincomycin
hydrochloride induced
diarrhoeal mice (9 days,
75 mg SP/kg BM)
After 9 d, seaweed polysaccharide group
vs. non-supplemented normal recovery
group (all differences p < 0.05):
Increase in beneficial Bacteroides,
Oscillospira and Bifidobacterium.
Decrease in Parabacteroides, Sutterella
and AF12.
Reduction in inflammatory cytokines,
TNF-α, IL-1β and IL-2.
Improved (lower) diarrhoea status
scores, water intake, and less weight loss.
Increase in total SCFA, acetate and
propionate.
[151]
** Fucoidan (300 kDa)
(60% fucose, 14.3%
sulphate)
C. okamuranus Method not specified
In vivo trial with Traf3
ip2-mutant psoriasis
mice (fucoidan diet
group n = 14, normal
diet group n = 9,
63 days, 1% fucoidan
added to feed)
Fucoidan group vs. cellulose control
group (all differences p < 0.05).
After 56 days:
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Increase (% relative abundance)
in Bacteroidetes (78.2 ± 6.42 vs.
59.4 ± 9.69%), Proteobacteria
(3.05 ± 0.62 vs. 1.73 ± 0.53%),
and Paraprevotellaceae.
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 Clostridium coccoi es (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
Es herich a coli (CF 7.16 ± .04, LPF 7.31 ± 0.05 a d HPF 6 96 ± 
0.04) gr ater than cellulose (6.81± 0.03) 
 Bif dobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
th n nulin positive control. HPF (68.9 μmol/mL) great r than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellul se 
 Butyric acid LPF (17.3 μmol/mL) > inul n n cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0. 0 ) a d LPF (1.18 ± 0.0 6) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 












(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± .15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lac obacillus
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on p pulations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoid s from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Decrease in Firmicutes
(16.3 ± 4.98 vs. 34.3 ± 9.05%) and
TM7 Saccharibact ria 3.80 ± .24
vs. 1.23 ± 0.11%).
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 B fidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulos  (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
After 21 days increase in mucin
production in ileum and faeces
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactoba illi (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 4 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to ellulose 
(1.22 ± 0.004)  Ra io f propi nic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF)
ompar d to 4.08 ± 0.18 ( nuli ) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
After 63 days incr ase in IgA
pro uction in cecum+
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inuli  (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
co pared to 4.08 ± 0.18 (in lin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Reduction in p oriasis area and
severity index (PASI) and
ethological scratch-test
Negative results:
– Decreases in Deferribacteres and







Laminaria hyperborea Method not specified
In vivo trial (10 pregnant
sows/treatment)
(10 g/days seaweed
extract from day 107 of
gestation until weaning




C mpared with non-supplemented
group, seaweed extract supplemented
(SWE) s ws had:
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) gr ater than cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6. 6 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA pr duction af er 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μ ol/mL) greater 
than inulin p sitive control. HPF (68.9 μmol/mL) greater than 
llulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Ac tic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic aci  CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
R tio f Firmicutes to Bacteroid tes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide cidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
i) LMW increased Bifid bact ria from 5.51 ± 0.15 log10 cells/mL (in 
cellul se fermented control) to .55  .08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no signific nt increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Greater colostrum IgA (p < 0.01)
and IgG (p = 0.062)
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Clost dium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin ( .57 ± 0.06) nd cellulo e (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellul se (6.81± 0.03) 
 Bifidobact ria (LP  7.11 ± 0.12) greater than cellulose (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inu in (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 Total SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Ac tic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic aci  CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
R tio f Firmicutes to Bacteroid tes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared t  cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 ( F), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellul se). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 




parturition (p < 0.05)
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 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
Es herich a coli (  7.1  ± .04, LPF 7.31 ± 0.05 a d HPF 6 96 ± 
0.04) gr ater than cellulose (6.81± 0.03) 
 Bi idoba teria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± .06) 
Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
Total S FA in CF (97.3 μmol/mL), LPF (89.0 μ ol/mL) greater 
than nulin positive control. HPF (68.9 μmol/mL) great r than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 A etic acid HPF (40.8 μ ol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/ L) > inulin and cellul se 
 Butyric acid LPF (17.3 μmol/ L) > in l n n cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0. 0 ) a d LPF (1.18 ± 0.0 6) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 












(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post ferme tation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± .15 log10 cells/mL (in 
cellulose f mented control) to 6.55 ± 0.08 log10 cells/mL; Lac obacillus
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on p pulations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoid s from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Reduced faecal Enterobacteriaceae
on exp ct d fa rowing date
(7.26 vs. 8.60 log10 CFU/g, pooled
SEM 0.463, p < 0.05)
LPS challenge increa ed
pro-inflammatory cytokines IL-1α and
IL-6 (p < 0.01) in ileal tissue and tumor
necrosis factor (TNF)-α in colonic
(p < 0.01) tissue
Piglets suckling SWE sows had:
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(ii and iii) 
Viscozy e and 
etha ol 
precipitation 
 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03)
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06)
 Lactobacilli (  6.56 ± 0.05) greater tha  i ulin (6.07 ± 0.05) and 
cellul se (5.11 ± .06) 
SCFA production after 24 h (all p < 0.05): 
 Total S FA n CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than i ulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μ ol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/ L) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicu s to Bactero detes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cellulose). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0. 5): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose ferme ted contr l) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Greater TNF-α after ex vivo LPS
challenge (p < 0.05)
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(ii and iii) 
Viscozy e and 
etha ol 
precipitation 
 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
inulin (7.57 ± 0.06) an  cellulose (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) greater than cellulose (6.81± 0.03)
 Bifidobacteria (LPF 7.11 ± 0.12) greater than cellulose (6.34 ± 0.06)
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± .06) 
SCFA production after 24 h (all p < 0.05): 
 Total S FA n CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than i ulin positive control. HPF (68.9 μmol/mL) greater than 
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Ac tic acid HPF (40.8 μ ol/mL) > cel ulose 
 Propionic acid CF 54.6 μmol/ L) > inulin and cellulose 
 Butyri  acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio f Firmicu s to Bactero detes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared t  cellulose 
(1.22 ± 0.004). Ratio of propioni  acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 ( F), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
compared to 4.08 ± 0 18 (in lin) and 5.73 ± 0.13 (cellul se). 





(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Increased seru IgG (p < 0.05) on
day 14
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(ii and iii) 
V scozy e and 
ethanol 
precipitatio  
 Clostridium coccoides (CF 8.29 ± 0.03, LPF 8.56 ± .06) greater than 
inulin (7.57 ± 0.06) and cellul s  (7.40 ± 0.05) 
 Escherichia coli (CF 7.16 ± 0.04, LPF 7.31 ± 0.05 and HPF 6.96 ± 
0.04) gr ater than cellulose (6.81± .03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than  (6.34 ± 0.06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
llulose (5.11 ± 0.06) 
SCFA production aft r 24 h (all p < 0.05): 
 T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater tha  
cellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Ac tic acid HPF (40.8 μmol/mL) > cel ulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared t  cellulose 
(1.22 ± 0.004). Ratio of propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 ( F), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF) 
c mpared to 4.08 ± 0 18 (inulin) and 5.73 ± 0.13 (cell l se). 




(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post fermentation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose fermented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Decr as d co o ic E. c li
population (p < 0.01) at weaning
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 Clost idi m coccoides (CF 8.29 ± 0.03, LPF 8.56 ± 0.06) greater than 
i ulin (7.57 ± 0.06) and cellulose (7.40 ± 0.05) 
 Escherichi  coli (  7.1  ± 0.04, LPF 7.31 ± 0.05 and HPF 6.9  ± 
0.04) greater han cellulose (6.81± 0.03) 
 Bifidobacteria (LPF 7.11 ± 0.12) greater than c llulose (6.34 ± .06) 
 Lactobacilli (LPF 6.56 ± 0.05) greater than inulin (6.07 ± 0.05) and 
cellulose (5.11 ± 0.06) 
SCFA production after 24 h (all p < 0.05): 
 T tal SCFA in CF (97.3 μmol/mL), LPF (89.0 μmol/mL) greater 
than inulin positive control. HPF (68.9 μmol/mL) greater tha  
ellulose (39.7 μmol/mL) but ~20% lower than inulin. 
 Acetic acid HPF (40.8 μmol/mL) > cellulose 
 Propionic acid CF (54.6 μmol/mL) > inulin and cellulose 
 Butyric acid LPF (17.3 μmol/mL) > inulin and cellulose 
Ratio of Firmicutes to Bacteroidetes beneficially lowered: HPF (1.08 ± 
0.008), CF (1.14 ± 0.001) and LPF (1.18 ± 0.006) compared to cellulose 
(1.22 ± 0.004). Ra io f propionic acid to acetic acid beneficially 
reduced: 0.47 ± 0.04 (CF), 0.62 ± 0.06 (LPF) and 2.15 ± 0.06 (HPF)
mpar d to 4.08 ± 0.18 (inulin) and 5.73 ± 0.13 (cell l se). 
* (i) Low MW 
polysaccharide (LMW) 
(prim rily laminarin) 
 
(ii) High MW 
polysaccharide acidic water 
extract (HMW) (primarily 
fucoidan and alginate) 
 
 
(iii) High MW 













(iii) Water and 
ethanol 
precipitation 
Simulated in vitro 
colonic digestion 
24 h post ferme tation (all differences p < 0.05): 
(i) LMW increased Bifidobacteria from 5.51 ± 0.15 log10 cells/mL (in 
cellulose f rmented control) to 6.55 ± 0.08 log10 cells/mL; Lactobacillus 
from 4.73 ± 0.13 (cellulose) to 5.28 ± 0.19 log10 cells/mL and 
Bacteroidetes from 5.09 ± 0.06 (cellulose) to 6.02 ± 0.09 log10 cells/mL. 
Negative results: no significant increase by LMW on populations of F. 
prausnitzii, Clostridium leptum, Ruminococcus bromii, E. coli or 
Enterococcus. 
(ii) HMW increased C. coccoides from 5.74 ± 0.75 (cellulose) to 7.07 ± 
0.04 log10 cells/mL, E. coli from 6.09 ± 0.41 (cellulose) to 7.52 ± 0.07 
log10 cells/mL and Enterococcus from 5.02 ± 0.31 (cellulose) to 6.63 ± 
0.11 log10 cells/mL. Negative results: no significant increase by HMW 
in any other bacterial populations. 
[148] 
Greater Lactobacilli: E.coli ratio
(p < 0.05)
Negative results:
– No increase in faecal volatile fatty
concentration in SWE sows
– SWE diet had no effect on TNF-α
mRNA xpression in
unchallenged sow ileal tissue
– Pigl t birth and weaning we ght,
and small intestinal mor hology
unaffected by SWE sow diet
[101]
* = in vitro studies; ** = in vivo animal studies.
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2.3. Polyphenols
Polyphenols are secondary metabolites that occur ubiquitously in terrestrial plants
and algae. They are composed of repeating units of phenol—an aromatic phenyl group
(a benzene ring, minus one hydrogen atom) bound to one or more hydroxyl groups [152].
Polyphenols are involved in numerous functions. They protect the seaweed thallus against
biotic and abiotic stresses such as predation from herbivores, microbial infection, oxidation,
and UV damage [153]. The total polyphenolic content of brown seaweed (dry mass) can
be as high as 20%, while green and red seaweeds contain 1–5% [154–156]. The molecular
weight of seaweed polyphenols ranges from approximately 26 Da to 650 kDa [157,158].
Seaweed polyphenols have been found to increase high-density lipoprotein cholesterol [159],
post-prandial cognitive function [160], and exert anti-hypertensive [161] anti-hyperglycaemic [162]
and peak blood glucose reducing effects (females only) [163] in human studies. However,
only 5–10% of polyphenols are absorbed in the upper gastrointestinal tract due to their
structural complexity. Large polyphenol compounds that reach the large intestine can be
converted by microbial activity into beneficial bioactive metabolites [164,165], while also
inhibiting pathogenic species [166]. Gut microbial enzymes catabolise polyphenols via
hydrolysis, dehydroxylation, decarboxylation, reduction, demethylation, and isomerisa-
tion [167]. Studies with germfree animals have shown that bioactive phenolic metabolites—
normally found after oral administration of polyphenols—are absent in their gut [168].
This shows the importance of the gut microbiota in polyphenol metabolism.
In terrestrial plants, the predominant polyphenols are flavonoids, stilbenes, lignans,
and phenolic acids [169]. Seaweeds also produce flavonoids, coumarins, phenolic ter-
penoids, phenolic acids, luteolin, regiolone, and neoeriocitrin as well other polyphenols
that are unique to algae [170–172]. These include bromophenols and phlorotannins [173].
2.3.1. Bromophenols
Bromophenols are molecules composed of one to five phenol groups, bound to one or
more bromine [174]. Bromophenols are produced by seaweed as part of their chemical de-
fence system to protect them from herbivores [175], oxidation, bacteria, and fungi [176,177].
Tri-bromophenols are the most common isomers found in seaweed, followed by di- and
mono- bromophenols [178]. Bromophenols occur most abundantly in red and green
seaweeds, and to a lesser extent in brown genera. A study of 49 red, green, and brown sea-
weeds by Whitfield et al. [179] reported bromophenol contents ranging from 8 to 2590 ng/g
in red, 0.9 to 2393 ng/g in green, and 2 to 454 ng/g in brown. Seaweed-derived bromophe-
nols have antioxidant [180], anti-inflammatory [181], antibacterial [182], anti-cancer [183],
antithrombotic [184], and antidiabetic [185] activity.
2.3.2. Phlorotannins
Phlorotannins, found only in brown seaweeds, are composed of repeating units of
phloroglucinol—a phenyl ring bound to three hydroxyl groups. Due to their ability to
precipitate proteins, they are considered tannins [186]. Phlorotannins have structural
functions within the seaweed cell wall [187], and protect against oxidation [188] and
predation by herbivores [189]. Phlorotannins are sub-classified into four main groups
depending upon the type of chemical bonds that link their phloroglucinol units [190].
Fuhalols and phlorethols have ether bonds; fucols have phenyl bonds; fucophlorethols
have phenyl and ether bonds; while eckols have dibenzodioxin bonds [191]. The molecular
weight of phlorotannins ranges broadly depending upon the number of phloroglucinol
units they contain [192]. Molecular weights have been reported from 1.2 to 6 kDa [193], 30 to
100 kDa [194], and as high as 300 kDa [195]. Phlorotannin content differs broadly amongst
species, and is influenced by seasonal variations and geographic location [196,197]. Content
is generally expressed as gallic acid or phloroglucinol equivalents, or as a percentage of
seaweed dry mass. A study of eight brown seaweeds over 14 months from the same
location in France by Connan et al. [196] reported significant inter- and intra-species
seasonal differences in phlorotannin content, with the highest values occurring in summer.
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Values ranged from 0.13% phlorotannin content (DW of total seaweed) in L. digitata, to 5.80%
in A. nodosum and F. vesiculosus. Phlorotannins have been studied for their potential health
effects. Reported bioactivities include antioxidant [198], antidiabetic [199], anticancer [200],
antihypertensive [201], anti-inflammatory [202], antiviral [203], neuroprotective [204],
antimicrobial [205], and prebiotic activities [10,206,207].
2.4. In Vitro and In Vivo Gastrointestinal Digestion Studies with Seaweed Polyphenols
The effect of polyphenols, particularly phlorotannins, on the gut, metabolic syndrome,
and DNA damage has been reported in some in vitro and in vivo studies which are discussed
below.
2.4.1. Prebiotic Function and Attenuation of Metabolic Syndrome by Phlorotannins
Charoensiddhi et al. [10] evaluated the prebiotic potential of phlorotannin enriched
(PE) ethanolic extracts in vitro from E. radiata harvested in Australia. After 24 h fermenta-
tion, the phlorotannin extracts induced significant increases (all p < 0.05) in some popula-
tions of beneficial bacteria, which were selected for the study due to their relevance to gut
health [10]. These were: Bacteroidetes (6.52± 0.04 log10 cells/mL) compared to the cellulose
control (6.40 ± 0.05 log10 cells/mL); F. prausnitzii (6.57 ± 0.05 log10 cells/mL) compared to
inulin and cellulose controls (6.17 ± 0.04 and 6.07 ± 0.06 log10 cells/mL, respectively); C.
coccoides (7.97 ± 0.05 log10 cells/mL) compared to inulin and cellulose controls (7.57 ± 0.06
and 7.40 ± 0.05 log10 cells/mL, respectively); and E. coli (8.09 ± 0.02 log10 cells/mL) com-
pared to inulin and cellulose controls (6.81 ± 0.03 and 6.94 ± 0.03 log10 cells/mL, respec-
tively). However, the production of SCFA was not enhanced by fermentation with the
phlorotannin extract.
Lin et al. [170] reported the effect of a polyphenolic extract from the green seaweed,
Enteromorpha prolifera, harvested in China, on the gut microbiome and glucose metabolism
of diabetic mice. Polyphenols were extracted from E. prolifera using ultrasound-assisted
ethanol and ultrafiltration to a MW of 3 kDa. The extract was characterised by UPLC-MS
and found to contain four polyphenols—luteolin-6-c-glucoside, regiolone, neoeriocitrin,
and estr-5(10)-ene-3,17-diol. Diabetes was induced in ICR mice (20/group) using STZ. Ten
of the diabetic mice received a high-sucrose/high-fat diet with no polyphenol supplement
(model group); while 10 received a high-sucrose/high-fat diet with E. prolifera polyphenol
extract (300 mg/kg BM/d) (diabetic group). A control group of non-diabetic mice received
standard chow (normal group).
After 28 days, there was an increase (p < 0.05) in the abundance of beneficial Alistipes
intestinal bacteria in the polyphenol-fed diabetic group compared to the model group.
After 14 days, there was a significant reduction (p < 0.05) in the mean BM of the E. prolifera-
fed diabetic group compared to the model group. After 28 days, fasting blood glucose
levels of the diabetic group were lower (p < 0.05), and glucose tolerance was increased
(p < 0.05) compared to the model group.
Histopathological analysis of the liver revealed that the polyphenol-fed diabetic group
had less cell damage and inflammation of the hepatic cord than the model group. The
mRNA expression of two proteins associated with glucose metabolism was also mea-
sured in liver tissue—phosphatidylinositol 3-kinase (PI3K) and c-Jun N-terminal kinase
(JNK). The PI3K pathway regulates insulin signal transduction and glucose homeosta-
sis [208], while over-activity of the JNK pathway is linked to insulin resistance and type-2-
diabetes [209]. After 28 days, mRNA expression of PI3K was increased in the diabetic group
(p < 0.01) compared to the model group, and was even significantly higher than the normal
group (p < 0.05). JNK1 expression in the diabetic group was successfully downregulated
by polyphenol supplementation and was lower (p < 0.05) than the model group.
Yuan et al. [210] investigated the ability of polyphenol extracts from the brown sea-
weed, Lessonia trabeculata, harvested in China, to alter the gut microbiota of rats in response
to type-2-diabetes. Microwave-assisted methanol extraction was followed by solvent frac-
tionation and macroporous resin adsorption separation. The polyphenol-rich fractions
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produced were composed primarily of phlorotannins, followed by phenolic acids and gal-
locatechin derivatives. Diabetes was induced in C57BL/6J rats using streptozotocin (STZ).
STZ damages the insulin-producing β cells of the pancreas, resulting in hypoinsulinaemia
and hyperglycaemia. Diabetic rats (8/group) (PE) were fed 200 mg/day polyphenol ex-
tract/kg BM along with their regular food for 4 weeks. A diabetes control (DC) group and
a normal control (NC) group (of non-diabetic rats) received no polyphenol supplement
with their food.
Hyperglycaemia, insulin resistance, and hyperlipidaemia were significantly (p < 0.01)
reduced in the diabetic rats after 4 weeks administration of the seaweed polyphenol extract.
Mean fasting blood glucose was lower (p < 0.05) in the PE group (10.55 ± 0.94 mmol/L)
compared to the DC control group (13.99± 0.87 mmol/L) as was serum insulin (14.69 ± 0.11
vs. 17.70 ± 0.22 mU/L (p < 0.01)). The homeostatic model assessment of insulin resistance
(HOMA-IR) value was lower in the PE group (p < 0.01) (6.89 ± 0.42 vs. 11.01 ± 0.98)
compared to the DC group. The reductions in lipid profiles in the PE group compared to
the DC group were: total cholesterol (4.92 ± 0.14 vs. 5.64 ± 0.16 mmol/L (p < 0.01)), triglyc-
erides (0.99 ± 0.04 vs. 1.43 ± 0.10 mmol/L (p < 0.01)), low-density lipoprotein cholesterol
(0.68 ± 0.03 vs. 1.06 ± 0.06 (p < 0.0)), glycated serum protein (2.15 ± 0.16 vs. 2.74 ± 0.15
(p < 0.01)) and non-esterified fatty acids (1.86± 0.05 vs. 2.02± 0.11 mmol/L (p < 0.05)). The
dyslipidaemia observed in the DC group who did not receive polyphenol supplementation
was most likely due to the deficiency of circulating insulin, which increases lipase activity
and fatty acid mobilisation from adipose tissue [211]. 16S rRNA gene sequencing of faecal
samples from the diabetic rats revealed that there was a significant (p < 0.01) increase in gut
bacterial diversity within the polyphenol-fed PE group compared to the DC and NC groups.
The PE group had a significantly greater abundance of Bacteroidetes, less Proteobacteria,
and an improved (lower) ratio of Firmicutes to Bacteroidetes compared to DC (p < 0.01).
An overabundance of Proteobacteria has been reported as a pro-inflammatory phylum
and linked with the imbalance of glucose homeostasis in type-2-diabetes [170]. At the
genus level, the PE group had approximately 10 times more Odoribacter (p < 0.008) and
Muribaculum (p < 0.005), and twice the population of Alistipes (p < 0.006), Lachnospiraceae
(p < 0.015) and Parabacteroides (p < 0.022) compared to the DC group. Lachnospiraceae
and Alistipes are butyric acid producing bacteria that contribute to the maintenance of
colonic epithelial tissue [212]. The Odoribacter genus, part of the Bacteroidetes phylum, is
an acetic, propionic and butyric acid producer. Its abundance ameliorates inflammation
by increasing SCFA availability [213]. An increase in Muribaculum and Parabacteroides
numbers has been reported to combat dyslipidaemia, weight gain, inflammation, and
insulin resistance resistance [214,215].
Quantification of gut SCFA showed a 61.1% increase in total SCFA production (from
491.31 ± 10.39 to 1276.34 ± 16.86 µg/g (p < 0.01)) by the rats after 4 weeks of polyphenol
supplementation. The PE group also produced 68.6% more acetic acid (1202.49 ± 11.55
compared to 377.77 ± 3.46 µg/g (p < 0.01)) and 74.4% more butyric acid (39.77 ± 1.85
compared to 10.18 ± 0.58 µg/g (p < 0.01)) than the DC group. The authors of the study
concluded that seaweed polyphenols may have regulated dysbiosis of the gut microbiota
in diabetic rats.
2.4.2. Impact of Digestion on Phlorotannin Bioactivity, Attenuation of DNA Damage, and
Cancer Cell Proliferation In Vitro
Corona et al. [216] studied the effect of in vitro gastrointestinal digestion and colonic
fermentation on the polyphenolic content and bioactivity of high molecular weight
(HMW > 10 KDa) and low molecular weight (LMW 1–10 KDa) ethanol-extracted phlorotan-
nins from A. nodosum harvested in Scotland. To assess changes in phlorotannin bioactivity
post-gastric digestion and -fermentation, the ability of the extracts to prevent H2O2 induced
DNA damage in HT-29 colon cancer cells and inhibit cell proliferation was also measured.
The HMW extract had the greatest total polyphenol and total phlorotannin contents before
and after digestion. The HMW extract also had the highest Trolox equivalent antioxidant
capacity. The molecular weight of total phlorotannins before and after gastric digestion
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and colonic fermentation was evaluated by normal phase HPLC. Gastric digestion reduced
the level of very high molecular weight components present in the HMW fraction by only
5.4%, while colonic fermentation caused an 89.9% reduction. In the LMW extracts, gastric
digestion reduced the level of very high molecular weight components by 52.8% and
colonic fermentation by 62.0%. In both cases, colonic fermentation had a far greater impact
on the breakdown of phlorotannins compared to enzymatic gastric digestion, suggesting
that phlorotannins have the potential to be metabolised by human gut bacteria.
A sulforhodamine B assay was used to measure changes in HT-29 colon cancer cell
biomass. The addition of post-gastric digested HMW and LMW at a concentration of
500 µg/mL significantly inhibited (p < 0.01) HT-29 cell proliferation (number of cells
by division), with HMW being the most effective. Post-gastric digested LMW did not
inhibit cell growth (mass accumulation) at any concentration, but HMW did (p < 0.05) at
concentrations of 250 and 500 µg/mL. High molecular weight phlorotannins may therefore
have a potential protective effect on colonocytes against cancer. H2O2 induced DNA
damage in HT-29 cells was evaluated by single cell gel electrophoresis (Comet) assay. Three
of the four phlorotannin extracts (at 100 µg/mL) were successful in reducing DNA damage.
Post-gastric digested HMW significantly (p < 0.01) reduced DNA damage compared to
the control, while post-gastric digested LMW had no effect. However, both the HMW
and LMW post-colonic fermented extracts significantly (p < 0.001) reduced DNA damage,
suggesting that colonic bacteria may potentially metabolise phlorotannins into molecules
with different bioactivity than their parent structures.
Although in vitro studies and animal trials do not replicate the human gut environment
identically, these results show that the abundance of bacteria which normally colonise
the mammalian gut may potentially be enhanced by the inclusion of dietary polyphenols.
The findings are an indication of prebiotic potential, which may be used to inform the
design of future human clinical studies. Table 2 summarises the polyphenol used in each
study and its potential impact on the gut microbiota in vitro and in vivo, the modulation of
hyperglycaemia in animal models, and attenuation of DNA damage in vitro.
Table 2. The potential impact of polyphenols on the gut microbiota in vitro and in vivo, modulation of hyperglycaemia in
animal models and DNA damage in vitro.
Polyphenol Seaweed Extraction Method Study Type Statistically Significant Effects Ref.
* Phlorotannin
enriched fraction E. radiata Ethanol (90%)
Simulated in vitro
colonic digestion
Increases (all p < 0.05) in
Bacteroidetes (6.52 ± 0.04 log10
cells/mL) compared to the
cellulose control (6.40 ± 0.05 log10
cells/mL); F. prausnitzii
(6.57 ± 0.05 log10 cells/mL)
compared to cellulose and inulin
controls (6.17 ± 0.04 and
6.07 ± 0.06 log10 cells/mL,
respectively); C. coccoides
(7.97 ± 0.05 log10 cells/mL)
compared to inulin and cellulose
controls (7.57 ± 0.06 and
7.40 ± 0.05 log10 cells/mL,
respectively); and E. coli
(8.09 ± 0.02 log10 cells/mL)
compared to inulin and cellulose
controls (6.81 ± 0.03 and
6.94 ± 0.03 log10 cells/mL,
respectively).
[10]
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Table 2. Cont.











In vivo trial with
diabetic mice
(4 weeks, 300 mg
polyphenol
extract/kg BM/day)
Reduction after 14 days (p < 0.05)
in mean BM of E. prolifera-fed
diabetic group compared to
model diabetic group.
Reduction after 28 days (p < 0.05)
in mean fasting blood glucose
levels of E. prolifera-fed diabetic
group and glucose tolerance
increased (p < 0.05) compared to
the model diabetic group.
Increase in Alistipes (p < 0.05) in
E. prolifera-fed diabetic group
compared to model diabetic
group.
Hypoglycaemic effect via increase
(p < 0.01) in phosphatidylinositol
3-kinase and suppression
(p < 0.05) of c-Jun N-terminal
kinase in E. prolifera-fed diabetic
















In vivo trial with




Increase in genera of the phylum
Bacteroidetes in the PE group
compared to the DC group:
Odoribacter (p < 0.008),
Muribaculum (p < 0.005),
Alistipes (p < 0.006),
Lachnospiraceae (p < 0.015) and
Parabacteroides (p < 0.022).
Decrease in Proteobacteria, and
ratio of Firmicutes to
Bacteroidetes (p < 0.05 PE vs. DC
group).
Increase in total SCFA
(491.31 ± 10.39 (DC),
1276.34 ± 16.86 µg/g (PE)
(p < 0.01)), acetic acid
(377.77 ± 3.46 (DC),
1202.49 ± 11.55 µg/g (PE)
(p < 0.01)) and butyric acid
(10.18 ± 0.58 (DC),
39.77 ± 1.85 µg/g (PE) (p < 0.01)).
Reduction in the PE group versus
the DC group in: fasting blood
glucose (10.55 ± 0.94 vs.
13.99 ± 0.87 mmol/L (p < 0.05)),
serum insulin (14.69 ± 0.11 vs.
17.70 ± 0.22 mU/L (p < 0.01)),
HOMA-IR insulin resistance
value (6.89 ± 0.42 vs. 11.01 ± 0.98
(p < 0.01)), total cholesterol
(4.92 ± 0.14 vs.
5.64 ± 0.16 mmol/L (p < 0.01)),
triglycerides (0.99 ± 0.04 vs.
1.43 ± 0.10 mmol/L (p < 0.01)),
LDL cholesterol (0.68 ± 0.03 vs.
1.06 ± 0.06 (p < 0.01)), glycated
serum protein (2.15 ± 0.16 vs.
2.74 ± 0.15 (p < 0.01)) and
non-esterified fatty acids
(1.86 ± 0.05 vs.
2.02 ± 0.11 mmol/L (p < 0.05)).
[210]
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Table 2. Cont.
Polyphenol Seaweed Extraction Method Study Type Statistically Significant Effects Ref.
(i) * Phlorotannin












(a) Reduction in MW of
phlorotannins (89.9% HMW,
62.0% LMW) by colonic
fermentation, compared to
enzymatic gastric digestion (5.4%
HMW, 52.8% LMW), suggesting
phlorotannins may potentially be
metabolised by human gut
bacteria.
(b) Compared to the control,
HMW and LMW phlorotannin
extracts at a concentration of
500 µg/mL inhibited (p < 0.01)
HT-29 colon cancer cell
proliferation (number of cells by
division),
HMW inhibited (p < 0.05) HT-29
cell growth (mass accumulation)
at concentrations of 250 and 500
µg/mL.
H2O2 induced DNA damage in
HT-29 cells reduced by
post-gastric digested HMW
extract (p < 0.01) and HMW and
LMW post-colonic fermented
extracts (both p < 0.001).
[216]
* = in vitro studies; ** = in vivo animal studies
2.5. Seaweed-Derived Peptides
Seaweed-derived peptides have reported bioactivity as inhibitors of renin [217], an-
giotensin converting enzyme-I (ACE-I) [9] dipeptidyl peptidase (DPP-IV) [218], platelet
activating factor acetylhydrolase (PAF-AH) [219] and α-amylase [220]. They also have
reported immunostimulatory [221], antitumor [222], anti-coagulant [223], antioxidative [5],
and anti-hyperglycaemic [224] activity. There is recent evidence that some peptides found
in vitro correlate with animal studies [225]. A study conducted by Fitzgerald et al. [217] pre-
viously identified the potential heart health beneficial effects of peptides included in a bread
product with peptides derived from the red seaweed Palmaria palmata using both in vitro
and animal models [226]. Peptides were isolated from the seaweed and characterised to
completion. However, another study carried out by Allsopp et al. [227] found that the same
seaweed had a pro-inflammatory effect when consumed as a whole seaweed in a bread
product. This highlights the importance of extraction and characterisation of seaweed
bioactives for potential use as therapeutic agents. Allsopp et al. suggested that the iodine
content of the seaweed may have been responsible for the observed pro-inflammatory
effect in a human dietary intervention study.
Table 3 details the amino acid sequences of recently elucidated seaweed peptides and
their bioactivities in vitro, in silico, or in vivo.
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Table 3. Amino acid sequences of recently elucidated seaweed-derived peptides and their bioactivities in vitro, in silico or in vivo.
Seaweed Extraction Method Amino Acid Sequence Bioactivity Ref.
* † U. lactuca
Enzymatic (Papain), MWCO
filtration, preparative RP-HPLC and










Amino acid sequences not defined:
(a) crude seaweed protein
(b) full peptide hydrolysate
(c) 1 kDa-UFH (ultra-filtered hydrolysate)
(d) 3 kDa-UFH
(e) 10 kDa-UFH
Peptides (i) to (vii) ACE-I, DPP-IV, and enzyme
3-hydroxy-3-methyl-glutaryl-CoA reductase
inhibition (in silico predictive activity)
In vitro ACE-I inhibitory activity (%) (all
assayed at conc. of 1mg/mL):
(a) crude seaweed protein 79.87 ± 0.18%
(b) full peptide hydrolysate 82.37 ± 0.05%
(c) 1 kDa-UFH (ultra-filtered hysrolysate) 93.03
± 0.87%
(d) 3 kDa-UFH 86.64 ± 2.17%
(e) 10 kDa-UFH 88.12 ± 0.02%
[9]
* P. palmata Enzymatic (Papain) Ile-Arg-Leu-Ile-Ile-Val-Leu-Met-Pro-Ile-Leu-Met-Ala
Renin inhibition
(58.97 ± 1.26% inhibition in vitro at 1 mg/mL) [217]





IC50 values in vitro:
(i) 43.40 ± 1.40 µM
(ii) 53.67 ± 0.82 µM
(iii) 159.37 ± 13.67 µM
[218]
* P. palmata Enzymatic (Papain) Asn-Ile-Gly-Lys PAF-AH inhibitionIC50 value in vitro 2.32 ± 2.12 mM
[219]
* Porphyra (Laver—species not
specified)
Enzymatic (Viscozyme, Alcalase,




IC50 values in vitro:
(i) 2.58 ± 0.08 mM
(ii) 2.62 ± 0.05 mM
[220]
* P. palmata Thermolysin hydrolysis (i) Leu-Arg-Tyr(ii) Val-Tyr-Arg-Thr
ACE-I inhibition
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Table 3. Cont.
Seaweed Extraction Method Amino Acid Sequence Bioactivity Ref.













(v) 18.8 µM(vi) 3.3 µM
(vii) 23.6 µM
In vivo antihypertensive effect in spontaneously
hypertensive rats (single oral dose, 1 mg/kg of
BW). Blood pressure decreases
(pre-administration vs. 9 h post):
(i) Val-Tyr (228.2 ± 3.4 vs. 206.7 ± 9.5 mmHg)
(p < 0.05)
(ii) Ile-Tyr (205.6 ± 5.2 vs. 184.3 ± 4.5 mmHg)
(p < 0.05)
(iii) Phe-Tyr (208.7 ± 4.4 vs. 193.0 ± 5.1
(p < 0.01)
(iv) Ile-Trp (213.3 ± 3.4 vs. 199.5 ± 5.9)
(p < 0.05)
[229]











* P. palmata Enzymatic (Protease) Ser-Asp-Ile-Thr-Arg-Pro-Gly-Gly-Asn-Met
Antioxidant activity after simulated
gastrointestinal digestion:
Oxygen radical absorbance capacity
152.43 ± 2.73 nM Trolox equivalents
(TE)/µmol peptide and ferric reducing
antioxidant power activity 21.23 ± 0.90 nM
TE/µmol peptide,
[231]
* = in vitro studies; ** = in vivo animal studies; † = in silico studies.
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Proteins and peptides can be used as a food substrate by some families of colonic
bacteria including Enterobacteriacea, Burkholderiacea, and Desulfovibrionacea [232] and
the genera Peptostreptococcus and Clostridium [233]. Most dietary proteins are broken
down by gastric enzymes in the upper gastrointestinal tract and absorbed by the host.
The remaining proteins and peptides that reach the colon are metabolised by microbial
proteases and peptidases via deamination or decarboxylation reactions to generate amino
acids or SCFA, which are used in proteolytic fermentation, or to build microbial cell
components [234,235]. The majority of microbial protein fermentation occurs in the distal
colon, after passing through the proximal colon, where carbohydrate fermentation is
dominant. Amino acids cannot be absorbed through the intestinal epithelium in the colon,
therefore protein fermentation end-products can accumulate. The majority of protein
fermentation end-products are branched-chain amino acids, while some bacteria such as
Clostridia and Fusobacteria metabolise peptides into beneficial SCFA [236–239]. Other
protein metabolites include hydrogen sulphide, phenylacetate, indoles, ammonia, and
p-cresol, an excess of which can impair epithelial barrier function [240]. However, this
has only been reported to occur in individuals with low fibre and high protein diets [241],
as the availability of complex polysaccharides reduces protein fermentation by the gut
microbiota [242,243].
2.6. Gastrointestinal Digestion Studies with Seaweed Peptides
Aside from being metabolised into amino acids and beneficial SCFA, seaweed-derived
peptides may potentially benefit the gut by enhancing the growth and proliferation of
intestinal epithelial cells.
Modulation of Intestinal Epithelial Cell Differentiation
Lee et al. [244] evaluated the ability of a 20 amino acid peptide extracted from the
red seaweed Porphyra yezoensis to modulate cell differentiation in rat intestinal epithelial
(IEC-6) cells. Cells were treated with the P. yezoensis peptide (PY-PE) at concentrations of
125, 250, 500, and 1000 ng/mL for 24 h. An MTS tetrazolium assay showed that the PY-PE
peptide significantly (p < 0.05) induced cell proliferation in a dose-dependent manner. Cells
treated with 1000 ng/mL PY-PE experienced the greatest increase in numbers (65%). In
order to decipher the mechanism by which the peptide exerted this effect, proteins related
to the insulin-like growth factor-I receptor (IGF-IR) signalling pathway were measured in
the cells. Four main insulin receptor substrate (IRS) proteins are involved in the pathway:
IGF-IR, IRS-1, sarcoma homology collagen (Shc), and phosphotyrosine (PY-99). These
substrates are adaptor proteins that send signals to the cell nucleus [245]. Protein and
mRNA expression of these substrates by the intestinal cells after treatment with PY-PE
was evaluated by western blotting, and reverse transcription-polymerase chain reaction
(RT-PCR) of complementary (c)DNA. After 24 h, PY-PE successfully upregulated protein
and mRNA expression of the four substrates, with the 1000 ng/mL PY-PE treatment having
the most significant (p < 0.05) effect.
The IGF-IR pathway in turn activates the mitogen-activated protein kinase (MAPK)
signalling pathway. MAPK is a kinase (phosphate transfer enzyme) that binds with
threonine and serine and directs cellular responses [246]. Expression levels of three MAPK
proteins were measured: extracellular signal-regulated kinase 1/2 (ERK1/2), anti-phospho-
c-Jun N-terminal kinase (JNK), and anti-phospho-p38 (P38). Treatment with PY-PE did
increase (p < 0.05) the expression of ERK1/2 in the intestinal cells in a dose dependent
manner; however, the peptide had no effect on JNK or p38. The authors surmised that the
peptide only affected ERK1/2 expression because it regulates cell growth and proliferation,
while JNK and p38 are activated by cellular stress and inflammation.
The effect of PY-PE on the PI3K-Akt signalling pathway was also examined by mea-
suring the intermediates p85, p110, PDK1, and p-Akt. This pathway is involved in cell
proliferation and angiogenesis through serine and threonine phosphorylation [143]. Com-
pared to the controls, protein and mRNA expression of p85, p110, PDK1 and p-Akt was
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increased (p < 0.05) in intestinal cells treated with PY-PE, dose dependently. Lastly, the
p42/p44 mitogen-activated protein kinase (MAPK1) pathway was investigated. This path-
way regulates the activation of transcription factors, such as activator protein-1 and its
sub-proteins, c-Jun and c-Fos, which modulate cell proliferation and differentiation. Again,
PY-PE treatment successfully upregulated protein and mRNA expression of c-Jun and c-Fos
in a dose dependent manner.
Due to these positive results, the authors of the study conducted further analysis
with the P. yezoensis derived peptide [247]. The proliferative effect of the peptide on the
epidermal growth factor receptor (EGFR) signalling pathway was investigated in IEC-6
rat intestinal epithelial cells. The EGFR signalling pathway influences cell functions such
as proliferation and involves several proteins including phosphorylated (p-)EGFR, Shc,
growth factor receptor-bound protein 2 (Grb2) and son of sevenless (SOS) [248]. Treatment
with the peptide (125–1000 ng/mL, 24 h) increased protein and mRNA expression of
p-EGFR, Shc, Grb2 and SOS in the intestinal epithelial cells. As in the previous study,
the greatest increases (p < 0.05) were induced by the highest concentration of peptide
(1000 ng/mL).
EGFR activates the Ras/Raf-p42/p44 MAPK signalling pathway, which mediates
signal transduction from the cell surface to the nucleus [249]. The P. yezoensis peptide
increased expression levels of the proteins involved in this pathway: Ras, Raf, mitogen
activated extracellular kinase (MEK), and p-extracellular signal-regulated kinase (ERK)
compared with the untreated control cells.
The expression of intestinal epithelial cell cycle-related proteins was also examined.
After 24 h treatment with the peptide, expression levels of proteins required for cell
proliferation—cyclin D1, cyclin E, Cdk2, Cdk4, Cdk6 and pRb—increased (p < 0.05). Con-
versely, the expression of two other proteins, p21 and p27, decreased following treatment
with the peptide. p21 and p27 are cyclin-dependent kinase inhibitors that regulate cell-cycle
arrest for the purposes of differentiation, DNA repair, and apoptosis [250]. Although they
are required for cell cycle completion, their over-expression has been linked to mucosal
damage and ulcerative colitis [251].
Finally, the effect of the P. yezoensis peptide on cell cycle progression was measured
using flow cytometry during the Gap 1 (G1) phase of cell division. Treatment with the
peptide (1000 ng/mL) induced increases of 47.6, 50.6, 56.8, 62.8 and 64.4% following
treatment with 0, 125, 250, 500, and 1000 ng/mL of peptide, respectively, in the proportion
of cells in the G1 phase. The authors concluded from the two studies that the peptide
derived from P. yezoensis seaweed has potential for development as a bio-functional food
which promotes the proliferation of intestinal epithelial cells.
The bioactivity of the P. yezoensis peptide was most likely due to the ability of its
structure to mimic the substrates of enzymes found in vivo, such as the kinases in the
above P. yezoensis studies. This is known as enzymatic antagonism. Peptides can inhibit
the catalytic action of enzymes on their substrates in a competitive, non-competitive,
or uncompetitive manner. Competitive inhibitors can mimic and compete with normal
substrates, binding with the active site of the enzyme in their stead. Non-competitive
inhibitors bind to allosteric sites on the enzyme, disrupting the conformational arrangement
of amino acids at the active site required for activity, thus preventing the substrate from
being able to bind. Uncompetitive inhibitors bind to the enzyme-substrate complex, which
changes its bioactivity [252]. Several peptides of algal origin have been shown to have
chemical structures with the ability to act as enzymatic antagonists [3,9,253–256].
Table 4 summarises the peptide used in each study and significant effects observed in
intestinal epithelial cells in vitro.
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Table 4. Seaweed-derived peptides and significant effects observed in intestinal epithelial cells in vitro.





In vitro rat intestinal epithelial
cells—investigating the modulation of cell
differentiation.
At concentrations of 125–1000 ng/mL, the peptide,
dose-depenently (p < 0.05):
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colonic digestion 
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Increased mRNA expression of p110, PDK1, p-Akt,






In vitro rat intestinal epithelial
cells—investigating the epidermal growth
factor receptor signalling pathway and
Ras/Raf-p42/p44 MAPK signalling pathway,
mediating signal transduction from cell
surface to nucleus.
At concentrations of 125–1000 ng/mL, the peptide
dose-dependently(p < 0.05):
– Increased mRNA expression of p-EGFR, Shc, Grb2,
SOS, Ras, Raf, mitogen act vated extracellular kinase,
and p-extracellular signal-regulated kinase.
– Increased mRNA expression of p-EGFR, Shc, Grb2,
SOS Ras, Raf, mitogen activated extracellular kinase,
and p-extracellular signal-regulated kinase.
– Increas d mRNA expression of proteins required for
cell proliferation: cyclin D1, cyclin E, Cdk2, Cdk4,
Cdk6, and pRb
– Increased cell growth during Gap 1 phase (47.6, 50.6,
56.8, 62.8 and 64.4% f llowing treatment with 0, 125,
250, 500, and 1000 ng/mL of peptide, respectively)
– Decreased RNA expression of p21 and p27
associated with mucosal damage and ulcerative
colitis.
[247]
* = in vitro studies.
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2.7. Bioaccessibility and Bioavailability
Bioavailability may be defined as the fraction of ingested nutrient or bioactive com-
pound that reaches the systemic circulation and is utilised by the body [257]. Numerous
factors influence the bioavailability of compounds in food including the health status of
the individual, age, diet, interactions with other dietary components during digestion, and
intestinal and hepatic metabolism [43,258]. Bioavailability involves two different phases—
bioaccessibility and bioactivity. Bioaccessibility is the quantity of the ingested compound
that is released from its food matrix and is available for absorption in the intestine [259].
Bioactivity is the biological activity of a drug or food component and involves transport of
the component to the target tissue, interaction with other biomolecules, biotransformation
and/or metabolism, and the induction of a physiological response [260].
The oral bioaccessibility of food can be measured in vitro using static or dynamic
digestive methods, or ex vivo using organ/tissue culture models. Bioavailability can be
measured using an animal-free method such as the protein digestibility-corrected amino
acid score for estimating in vivo protein digestibility [261], but is usually measured in vivo
using animal or human models [262]. The advantages and limitations of in vitro versus ex
vivo and in vivo methods are here outlined.
2.7.1. In Vitro Bioaccessibility Methods
In vitro simulated digestion methods are generally used as a preliminary test to de-
termine the oral bioaccessibility of a food-derived component as they can be conducted
in a laboratory using chemicals and enzymes that mimic the environment of the stomach
and intestine without the need for live animals or human participants [263]. Experimental
processes for in vitro simulated digestion involve several incubation steps (1–3 h) of the
sample at physiological temperatures (37 ◦C) and conditions that simulate the mammalian
digestive tract [264]. Oral digestion of the homogenised food sample begins with lingual
α-amylase at pH 5–7, followed by adjustment of pH to 1–3 to mimic the stomach environ-
ment and the addition of the endopeptidase, pepsin [36]. Finally, the pH is adjusted to
6–8 to mimic the small intestine and pancreatin (a combination of amylase, protease, and
lipase) is added with or without bile [265].
In vitro methods are divided into four categories: these are solubility, dialysability,
gastrointestinal models, and cell models [245].
Solubility and Dialysability
Solubility involves centrifugation of the digested sample and quantification of the
nutrient of interest in the supernatant by various techniques such as atomic absorption
spectrophotometry (AA), mass spectrometry and HPLC [266]. Laparra et al. [267] estimated
the bioaccessibility of arsenic in Hizikia fusiforme, Porphyra and Enteromorpha species using
an in vitro solubility method followed by AA.
Dialysability was first described by Miller et al. [268] in 1981 to measure the bioaccessi-
bility of iron by equilibrium dialysis, and has been modified to quantify the bioaccessibility
of other micronutrients. After acidic pepsin digestion of the food sample, dialysis tubing of
the required MW is filled with a basic buffer such as sodium bicarbonate and added to a
vessel containing the sample in its acidic environment. The sodium bicarbonate diffuses
out of the dialysis tubing and neutralises the acidity. Pancreatin is added to the sample and
incubated. The dialysate that diffuses in through the tubing is the bioaccessible portion of
the food sample, which is then removed from the vessel and quantified [268].
Static and Dynamic Gastrointestinal Models
Gastrointestinal models can be static or dynamic. Static models are the simpler of the
two methods and involve the oral, gastric, and small intestinal stages described above. The
reactions are carried out in a single bioreactor or flask with stirring and pH adjustments
made at each step by addition of an acid or base, usually hydrochloric acid and sodium
hydroxide [260]. One of the limitations of static methods is the broad variance in results
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due to the diversity of reagents used worldwide, particularly digestive enzymes, that differ
in activity depending upon their source, which can be human, porcine, rabbit, bacterial,
or fungal [269]. Other parameters such as incubation time, pH, ionic strength, the use of
phospholipid surfactants, bile salts, and sample to liquid ratio also vary from one method to
another [270]. In order to address this lack of cohesion in simulated digestive methods, the
European Cooperation in Science and Technology (COST) began an EU-funded Action in
2011 called INFOGEST involving scientists from 45 countries [271]. In 2014, an international
consensus was reached and a standardised static in vitro digestion method suitable for food
was published by Minekus et al. [269] based on physiologically relevant conditions that
can be applied for various endpoints. The method recommends specific concentrations and
conditions for each step of static in vitro digestion. Pepsin was determined to be the factor
causing most variation, the activity determination of which was found to be improved by
pH stabilisation [269]. Subsequent inter-laboratory validation studies in 2016 by Egger
et al. [265] using skim milk powder as a model food found that the harmonised INFOGEST
method delivered increased consistency for the comparability of in vitro digestion studies.
Recent studies have used the INFOGEST method to evaluate the potential bioaccessibility
of seaweed components such as essential minerals [272], carrageenan [273], and to assess
protein digestibility [274]. Static models have the advantage of being inexpensive, easy to
use, and do not require specific equipment. However, continuous mechanical agitation is
not representative of complex peristaltic movements and does not replicate the dynamic
processes that occur during digestion, such as continuous changes in pH and secretions or
gastric emptying [275].
Dynamic gastrointestinal models differ from static models in that a series of chambers
are used to digest the food sample connected by peristaltic pumps [276]. The temperature,
pH, enzyme concentration, incubation time and agitation-rate of each chamber is controlled
by a computer [264]. The first commercial dynamic gastrointestinal model was developed
in 1995 by Minekus et al. [277] at the Netherlands Organisation for Applied Scientific
Research (Toegepast Natuurwetenschappelijk Onderzoek (TNO)) called the TNO Gastro-
Intestinal Model (TIM). The TIM-1 model has four compartments, representing the stomach,
duodenum, jejunum, and ileum connected by peristaltic valve pumps. Bioaccessible frac-
tions are collected by dialysis after the fourth compartment [277]. The non-bioaccessible
fraction is transferred to the TIM-2 model, which has one compartment representing the
large intestine. Human faecal inocula is added to study the effect of colonic fermentation
on the food sample and nutrient absorption [277]. The main advantage of the TIM system is
that it is a holistic in vitro gastrointestinal model which incorporates the large as well as the
small intestine. In addition, samples can be taken at any stage of the digestive process with-
out pausing the experiment [278]. Several studies have found that bioaccessibility results
using the TIM system correlate with bioavailability of the same nutrient in vivo. The TIM
system was used to measure the bioaccessibility of iron and phosphorus from wheat [279];
folate in folate-fortified milk products [280]; and the bran, flour, and protein aleurone layer
of wheat [281] and were found to be comparable to in vivo data. The TIM system has been
used to assess the bioaccessibility of heavy metals [282] and essential minerals [283] in
seaweed. Drug bioaccessibility was assessed in a study by Blanquet et al. [284] compar-
ing the ability of TIM-1 to measure the bioaccessibility of paracetamol and a lyophilised
Lactobacillus strain with in vivo data. The TIM1 results were consistent with in vivo data,
showing the value of TIM-1 as a predictive tool on biopharmaceutical behaviour. However,
as with all in vitro methods, in vivo factors such as first pass effect, renal clearance, and
metabolisation by intestinal epithelial are not represented [284].
The Institute of Food Research in Norwich, England also developed a dynamic method,
published by Wickham et al. [285] in 2012, called the Dynamic Gastric Model (DGM). It
was designed to simulate the discrete mechanical aspects of gastric digestion as well as
the biochemical and is more complex than earlier dynamic models [276]. The masticated
sample is added slowly over the course of several minutes to mimic the swallowing of
food. The DGM system has several functionally distinct zones in which the masticated
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food bolus is processed to mimic the human stomach environment. A secretion distributer
gradually introduces gastric acid and enzymes to the flexible main body around the food
bolus, which is then gently kneaded. Contents then move to the antrum, where they are
subjected to physiological shear and grinding forces [285]. The sample, or chyme, can be
removed at this stage or further digested in the duodenal chamber with pancreatic enzymes,
bile salts, lecithin and cholesterol, which is often used for gastro-resistant pharmaceutical
formulations to monitor dispersal and dissolution in the duodenal phase [276]. A study
by Vardakou et al. [286] compared the disintegration and dissolution capabilities of the
DGM system with a standard Dissolution Apparatus USP-II using agar gel beads, and
compared the results to those previously observed when the same beads were given to
human volunteers [287]. The DGM system was found to be superior to the Dissolution
Apparatus USP-II, and there was no significant difference between the human trial data
and the DGM, indicating that it is comparable to the mechanical forces exerted by the
human gastric digestion [286]. Dynamic gastrointestinal models are more representative
of human gastrointestinal digestion because they simulate the changing physicochemical
conditions and peristaltic forces of the gastrointestinal tract; however, they are more costly
and have lower throughput than static models [264].
Although models concerning digestion and bioaccessibility determination of food
bioactives are commonly used in research today, along with colonic digestion methods,
they are not always accurate or fully representative of bioactive digestion. This is because
every gut has a unique microbiome that cannot currently be replicated in in vitro simulated
models. In addition, the gut proteome plays a role in the products available for uptake.
However, in vitro simulated models do provide a useful guide concerning the breakdown
of foods/food bioactives by enzymes in the stomach and gut. Further development of
in vitro static and dynamic models is required to give a true representation of how the
microbiome and proteome of the gut impact digestion of seaweed and food bioactives.
Comparisons between static, dynamic, colonic and animal studies using pigs are necessary
to improve these models [225].
Cell Models
The fourth category of in vitro methods is the cell culture model. In vitro-differentiated
human and other mammalian epithelial cell monolayers that are representative of intestinal
epithelial cells can be used to mimic the ability of food components to be absorbed, and
actively or passively transported and assimilated across the intestinal epithelium [288].
Cell lines commonly used for bioaccessibility studies include Caco-2, HT-29 [289], GLUTag,
murine STC-1, human NCI-H716, [290], and porcine IPEC-J2 [291]. The Caco-2 cell line
is a human colon carcinoma cell line which has been extensively used in gastrointesti-
nal studies due to its spontaneous differentiation forming a monolayer of cells, which
express several morphological and functional characteristics of the mature enterocyte [292].
Glahn et al. [293] expanded upon the earlier in vitro membrane diffusion method described
by Miller et al. [268] by developing a model for assessing bioaccessibility using Caco-2 cells
to measure nutrient uptake after simulated peptic and intestinal digestion of casein and var-
ious meats. The method was designed to measure iron uptake by cells but can be applied
to other micronutrients. The Glahn method overcomes the issue of damage to Caco-2 cells
by digestive enzymes. Normally, if a food sample that had been digested in pepsin and
pancreatin were added to the media in which cells were growing, the enzymes could digest
the protein structure of the cells. The Glahn method utilises a 12,000–14,000 MW cut-off
dialysis membrane to allow iron (or other nutrient of interest) to diffuse through onto the
cells, while the larger enzyme molecules are held back. The iron that is absorbed by the cells
can then be measured. The results using this method parallel human in vivo absorption
studies [293]. It has been used recently by Trigo et al. [294] to determine the bioaccessibility
of seaweed bioactives. Flores et al. [295] and Domínguez-González et al. [296] also used the
Glahn cell culture method to assess the bioavailability of iron and iodine from seaweeds.
The lack of mucus production by Caco-2 cells can be a disadvantage for some studies,
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but may be overcome by co-culturing with a human mucus-producing cell line, such as
HT29-MTX to more closely resemble in vivo conditions [288].
In summary, advantages of in vitro methods over ex vivo and in vivo include their
low cost, large-scale capacity, high-throughput, and obviation of the need for human
volunteers or animal testing, which is more ethical. The major limitation is the absence of
the true physiological conditions of the human digestive tract such as peristalsis, phase
I/II metabolism, bio-distribution, and renal excretion [262,297]. In vitro methods also do
not fully reflect the conditions that affect digestibility in vivo such as interaction of the
food sample with other macro- and micro-nutrients, fibre, anti-nutritional components
such as phytic acid and lectins, gastric enzyme specificity, and the different absorptive
capacities at each stage of the gastrointestinal tract [270,298–300]. In vitro methods offer a
good preliminary measure of bioaccessibility, but bioavailability, which has a physiological
or metabolic endpoint, cannot be fully quantified by in vitro methods [263,266].
2.7.2. Ex Vivo Bioavailability Methods
Ex vivo organ or tissue models are also used to measure the oral bioavailability of
bioactive food components. Ex vivo methods use living functional tissues or organs taken
from an organism and maintain it in its natural physiological state [301]. The concept was
first developed by Ussing [302] in 1946 to measure the active transport of sodium chloride
ions in solution across frog skin. This was further developed into the Ussing chamber
model, which quantifies the transport of ions, nutrients, or drugs across any epithelial tissue
by measuring the potential or voltage difference that is produced as the sample diffuses in
solution from one side of the epithelium to the other [303]. For oral bioavailability studies,
the required mammalian intestinal mucosal tissue (from duodenum to colon) is mounted
between two small chambers of buffered Ringer solution. The compound of interest,
along with isotopic tracers, is added to the chamber on the lumenal (apical) side of the
epithelium. To mimic haemoglobin delivery by arterial blood, levels of oxygen (95%) and
carbon dioxide (5%) are maintained [304]. The active transport of the compound of interest
by the epithelial cells from lumenal to mucosal side is measured by voltage difference.
Interference by passive transport forces such as osmotic and electrochemical gradients is
cancelled out by passing an electrical current of zero potential through the epithelium [303].
Advantages of the Ussing chamber model are its precision in measuring the electrical and
transport parameters of intact epithelium, and the ability to study any type of intestinal
epithelium, as well as others such as the placental barrier [275]. Its main limitations include
relatively low-throughput, extensive preparation, short viability (150 min), and limited
range of measurements that do not fully describe the complex physiological system of the
intestinal mucosa [305].
An intestinal segment model was developed to obtain a higher throughput ex vivo
screening system compared to the Ussing chamber model [306]. The intestinal segment
model was first described in 1954 by Agar et al. [307] to measure the uptake of histidine
by rat intestinal segments. The intestinal segment model measures the absorption of
compounds into the intestinal cells rather than their transport through the epithelium [308].
It also involves the use of numerous sections of epithelial tissue which are cut from the
original and placed in physiologically balanced solution instead of being mounted, as in
the Ussing technique [307]. The porcine ex vivo intestinal segment model is most commonly
used due to the physiological resemblance of human and pig intestines [309]. Small circles
of tissue segments are punched out and incubated in buffer in 24-wells plates with the
test compound. After incubation, the quantity of the test compound absorbed by the
intestinal segment is quantified [310]. The intestinal segment model has advantages over
the Ussing chamber model in that it is less labour intensive and has a significantly higher
throughput [310].
The advantage of ex vivo organ models, in general, over single cell lines is that they
are a multi-cell system and therefore more representative of intestinal epithelial behaviour
in terms of food absorption [311,312]. Compared to in vivo studies, ex vivo organ models
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remove the need for human participants. Limitations of ex vivo organ models include the
lack of inclusion of gut microbial influence and time constraints. The epithelial intestinal
tissue must be excised from the animal within ~5 min of sacrifice, and the viability of
intestinal tissues once the experiment begins is only ~150 min and therefore not suitable
for many oral bioavailability studies that require more time [313]. The intestinal segment
model has the added disadvantage of no distinction between the apical and basolateral
side of the epithelium in the way that the mounted Ussing model does, as the segments are
completely submerged in the same solution on both sides [314].
2.7.3. In Vitro Fermentation Models
In vitro fermentation models allow the impact of gut microbial populations on food
bioaccessibility and bioactivity to be studied without using invasive human or animal
methods. Batch or dynamic fermentation models can be used [315]. Batch fermentation
models entail the use of a sealed vessel under anaerobic conditions containing the food
sample or extract of interest in sterile media to which is added either a pure, or mixed,
bacterial culture or faecal slurry, fermented for ~2 to 24 h [316]. The advantage of batch
models is that they are simple to set up and inexpensive, however, since it is a static
sealed model, fermentation products such as SCFA can accumulate, and there is a finite
amount of substrate available for the bacteria, all of which can affect the fermentation
environment [316]. Dynamic multistage models can be used to overcome this issue. In 1988,
Gibson et al. [317] first described a three-stage continuous culture system with a mixed
human faecal inocula fermented over 120 days that represented the environment of the
proximal, transverse and distal colon. Since the 1980s, more sophisticated, computerised
dynamic models have been developed including the TIM-2 (previously discussed), The
Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) and SIMulator of the
GastroIntestinal tract (SIMGI).
The SHIME model is a 5-step multi-chamber bioreactor developed by Molly et al. [318]
in 1993 that simulates the entire digestive tract from stomach to colon. The SHIME sys-
tem involves allowing the microbial inoculum acclimate for 14 to 20 days to produce an
environment that is representative of the in vivo colon in terms of bacterial populations
and SCFA production [319]. Two advanced models have been developed from the original
SHIME system—TWIN-SHIME and M-SHIME. Possemiers et al. [320] devised the first
TWIN-SHIME model, which involves running two parallel SHIME reactors, making it
possible to assess the impact of different diets or antibiotics on the same gut microbiota, as
well as the metabolism and bioaccessibility of nutrients, and the pre- and probiotic effect
of selected foods or microorganisms. Van den Abbeele et al. [321] incorporated mucin-
covered microcosms in the M-SHIME model to create a more realistic microbial community
of mucosal microbes such as Lactobacillus mucosae and Pediococcus acidilactici that are nor-
mally present on the gut epithelium. The SHIME model was used by Marzorati et al. [322]
to investigate the potential of fucoidan to modulate a gut bacterial community, and by
Fu et al. [323] and Calatayud et al. [324] to evaluate the effect of gut microbiota on the
bioaccessibility of arsenic from the seaweeds Hizikia fusiforme and nori.
Advantages of SHIME include realistic representation of the upper and lower digestive
tracts rather than the colon alone; long-term stability of the microbiome, which can be
assessed as it adapts; option to set the model to parameters found in diverse groups such
as humans, animals, diseased, healthy, elderly, or infants (Baby-SHIME) [325]; parallel
comparison of alternate treatments (TWIN-SHIME); and ability to create a luminal or a
mucosal microbiome (M-SHIME) [318,326,327]. Limitations of the SHIME model include
a lack of realistic peristalsis, expensive set-up costs, and absence of a dialysis component
and mucosal cells (in the original model) [326].
The SIMGI multicompartmental dynamic model is another five-chamber system that
represents the entire human intestinal tract, developed by Barroso et al. [328] in 2015. It
differs from other dynamic models in that the contents of the stomach chamber are mixed
by peristaltic movements. Two rigid outer chambers surround an inner unit with flexible
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silicone walls. Alternating the pressure of the water flow between the outer chambers
and inner unit creates a realistic simulation of gastric peristalsis [329]. The SIMGI system
has the same advantages and limitations as the original SHIME model. However, SIMGI
has the unique advantage of the inclusion of simulated peristalsis that is not found in
SHIME or any other dynamic models, creating a more mechanically realistic stomach
environment [329].
Overall, the advantage that all dynamic models have over static models is that they
more closely represent the human gut because pH and nutrient availability within each
chamber are controlled throughout the fermentation process, which also allows for much
longer experiments than static batch models [330]. Dynamic models have good experimen-
tal stability and reproducibility [331]. Samples can be taken from each chamber during
fermentation to assess changes in bacterial populations and their metabolites, and the
ethical constraints that limit in vivo trials are absent [332]. Limitations of dynamic models
include the lack of intestinal epithelial and immune cells in some systems; lack of host-
microbe interplay [333]; no feed-back mechanisms in the system; and the use of parameters
such as pH, redox potential, and transit time based on healthy individuals which may not
be representative of many groups [334].
2.7.4. In Vivo Bioavailability Methods
The most accurate method for measuring the bioavailability of a food component is
in vivo evaluation [335]. In vitro and ex vivo methods provide very useful data on bioacces-
sibility, and to a certain extent, bioavailability if cell models are used but they can never
fully express the digestive fate of a food component in a living person or animal. This
is primarily due to the complex metabolism that occurs during absorption, where food
metabolites reaching the blood system may be different from the original compounds [336].
Bioavailability involves the phases of liberation, absorption, metabolism, tissue distribu-
tion, bioactivity, and elimination [257]. Balance studies can be used to measure the oral
bioavailability of a nutrient by the amount that is eliminated. This entails the collection
of all urine and stools after giving a known amount of the nutrient to test subjects over
several days or weeks [337]. Balance studies provide accuracy, but are laborious and more
suited to laboratory animal models than human subjects [338]. Tissue distribution studies
also provide bioavailability data on the extent of absorption, but are almost exclusively
conducted on animals due to the invasive nature of the procedure [339,340]. In human
in vivo studies, the oral bioavailability of a bioactive food component is most commonly
measured by analysis of its metabolites in blood plasma and/or urine after a single dose,
or controlled long-term consumption [336,341]. These are the methods used in the seaweed
bioavailability studies discussed in the following sections.
Although in vivo studies are considered the gold standard for assessing the oral
bioavailability of food components [263] some disadvantages exist. Compared to in vitro
and ex vivo models, obtaining ethical approval for in vivo studies is far more difficult due
to the potential harm that may be caused to animal or human participants, and in many
cases, the necessary sacrifice of animal subjects [43]. In vivo studies are generally more
expensive and time-consuming than other methods [342] and are not suitable for high-
throughput screening of bioavailability [343]. It is more difficult to control all variables
in vivo because of naturally occurring differences in living organisms, which can affect the
reliability of results [344]. In vivo trials involving small cohorts may not be reflective of the
bioavailability of a nutrient in the wider population [345].
However, these limitations are ultimately outweighed by the advantages. In vivo
studies reflect the complete effect of digestion, first pass metabolism, Phase I/II biotrans-
formation, host microbiota, and fermentation on an orally consumed nutrient [43,257]. In
addition, in vivo studies show the impact of the nutrient on the body as a whole, rather
than in one localised area or on one particular biological process [342]. Data from in vivo
studies is more clinically relevant and any side-effects induced by the consumed sample
can be observed [262,346]. Although gaps exist in in vitro methods of measuring digestion
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and bioavailability compared to animal models, in vitro studies still provide very relevant
and useful data regarding bioaccessibility.
Table 5 summarises the advantages and limitations of each gastrointestinal digestion
model system.
Table 5. Advantages and limitations of gastrointestinal (GI) digestion model systems.
In Vitro Bioaccessibility Methods Advantages Limitations
Solubility and Dialysability
• Simple and inexpensive to conduct with
enzymes and dialysis filters that chemically
mimic oral, gastric and small intestinal
digestion
• Inexpensive
• No human or animal subjects required
• Does not represent peristaltic movements,
secretions, or gastric emptying of the GI
tract
• No gut microbial component
Static GI models
• Simple to conduct in single bioreactor or
flask with stirring and pH adjustments
• Inexpensive
• No human or animal subjects required
• Broad variance in results due to reagent
diversity, particularly digestive enzymes
which differ in activity dependent on their
source (human, porcine, rabbit, bacterial,
or fungal)
• Continuous mechanical agitation is not
representative of complex peristaltic
movements, secretions, or gastric
emptying of the GI tract
• No gut microbial component
INFOGEST static in vitro model
• Addresses worldwide lack of cohesion in
simulated digestive methods
• Standardised static method suitable for food
based on physiologically relevant conditions
which can be applied for various endpoints
• Pepsin determined to be the factor causing
most variation—activity determination may
be improved by pH stabilisation
• Inexpensive
• No human or animal subjects required
• Continuous mechanical agitation is not
representative of complex peristaltic
movements, secretions, or gastric
emptying of the GI tract
• No gut microbial component
Dynamic GI models
• Holistic in vitro gastrointestinal model
incorporating the large and small intestine
• More representative of human GI digestion
as changing physicochemical conditions and
peristaltic forces are simulated in
functionally distinct zones
• Human faecal inoculum included to study
the effect of colonic fermentation on the food
sample and nutrient absorption
• Samples can be taken at any stage of the
digestive process without pausing the
experiment
• Bioaccessibility results of dynamic models
have been shown to correlate with
bioavailability of the same nutrient in vivo
• No human or animal subjects required
• More costly and lower throughput than
static models
• Lack of in vivo factors such as first pass
effect, renal clearance, and metabolisation
by intestinal epithelial cells.
Mar. Drugs 2021, 19, 358 28 of 50
Table 5. Cont.
In Vitro Bioaccessibility Methods Advantages Limitations
Cell models
• Representative of intestinal epithelial cells
• Parallels human in vivo absorption studies
• May be used to mimic the ability of food
components to be actively or passively
transported and assimilated across the
intestinal epithelium
• Human cell lines can be used as well as
animal cells
• Mucus-producing cell lines can be
co-cultured to more closely resemble in vivo
conditions
• Time-consuming to culture cell lines
• Costly
• First pass effect, renal clearance, interaction
of the food sample with other nutrients
and anti-nutrients, and different absorptive
capacities at each stage of the
gastrointestinal tract are not represented
Ex vivo bioavailability methods
• Multi-cell systems are more representative of
intestinal epithelial behaviour in terms of
food absorption than single cell lines
• Animal organ or tissue models can measure
the oral bioavailability of bioactive food
components
• Mimics arterial blood haemoglobin delivery
by maintaining oxygen and carbon dioxide
levels
• Precise measurement of electrical and
transport parameters of intact epithelium
• Any type of intestinal epithelium from
duodenum to colon can be studied, as well as
other epithelia, such as the placental barrier
• No human subjects required
• Extensive preparation
• Lack of inclusion of gut microbial influence
• Low throughput (mounted tissue models,
such as Ussing chambers)
• Intestinal segment models have greater
throughput, but no distinction between
apical and basolateral side of the
epithelium as tissue segments are fully
submerged
• Short viability–epithelial intestinal tissue
must be excised from animal within ~5
min of sacrifice
• Viability of intestinal tissues once the
experiment begins is only ~150 min and
not suitable for many oral bioavailability
studies that require more time
• Limited range of measurements that do not
fully describe the complex physiological
system of the intestinal mucosa
In vitro fermentation models
• Static batch or dynamic fermentation models
can be used
• Batch models are simple to set up and
inexpensive
• Evaluates the impact of gut microbial
populations on food bioaccessibility and
bioactivity without using invasive human or
animal methods
• Dynamic multistage models overcome the
issue of fermentation product build-up in
static batch models. pH and nutrient
availability within each chamber are
controlled throughout fermentation
• Computerised dynamic models such as
TIM-2, SHIME and SIMGI create an
anaerobic environment representative of the
upper and lower digestive tracts rather than
the colon alone in terms of bacterial
populations and SCFA production
• Long-term stability of the microbiome—can
be assessed as it adapts
• SHIME has option to set parameters found in
diverse groups—humans, animals, diseased,
healthy, elderly, or infants, and compare
alternate treatments in parallel
• Possible to create a luminal or a mucosal
microbiome
• Easier to obtain ethical approval compared to
in vivo studies
• Dynamic multistage models are costly and
complex to set-up
• In static sealed batch models, fermentation
products such as SCFA and p-cresol can
accumulate and there is a finite amount of
substrate available for the bacteria
• Lack of realistic peristalsis; expensive
set-up costs; and absence of a dialysis
component and mucosal cells (in the
original SHIME model)
• Lack of realistic peristalsis in SHIME
model and absence of a dialysis component
and mucosal cells (in the original model)
• Lack of intestinal epithelial and immune
cells in some systems. No feed-back
mechanisms
• Use of parameters such as pH, redox
potential, and transit time based on healthy
individuals may not be representative of
many groups
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Table 5. Cont.
In Vitro Bioaccessibility Methods Advantages Limitations
In vivo bioavailability methods
• Considered the gold standard and most
accurate method for measuring
bioavailability – analysis of metabolites in
blood plasma and/or urine after a single
dose, or controlled long-term consumption
• Reflects complete effect of digestion, first
pass metabolism, Phase I/II
biotransformation, host microbiota and
fermentation on an orally consumed nutrient
• Balance studies collecting urine and stools to
measure oral bioavailability are accurate
• Tissue distribution studies provide
bioavailability data on the extent of
absorption
• Data from in vivo studies is more clinically
relevant and any side-effects induced by the
consumed sample can be observed
• Balance studies are laborious and more
suited to laboratory animal models than
human subjects
• Tissue distribution studies almost
exclusively conducted on animals due to
invasive nature
• Difficult to obtain ethical approval due to
potential harm to animal or human
participants and sacrifice of animals
• Usually more expensive and
time-consuming than other methods
• Not suitable for high-throughput screening
of bioavailability
• More difficult to control all variables due
to naturally occurring differences in living
organisms
• In vivo trials involving small cohorts may
not be reflective of the bioavailability of a
nutrient in the wider population
A number of recent studies have evaluated the bioaccessibility of seaweed-derived
polysaccharides, polyphenols, and peptides after ingestion in human and animal subjects
and are discussed below.
2.7.5. Bioaccessibility of Seaweed Polysaccharides
Gueven et al. [347] showed that a single dose of orally ingested fucoidan is sufficient to
affect the expression of genes related to immunity, inflammation, cancer, and neurological
function. A placebo-controlled double-blind study was performed in nine healthy, male
volunteers (age 25–65 years-old). Fucoidan (85.1% pure, MW 47.7 kDa) was water-extracted
from U. pinnatifida harvested in Tasmania. A capsule containing 1 g seaweed extract
(851 mg fucoidan) or a cellulose placebo was administered. Blood was taken immediately
before and 24 h after ingestion. 754 micro RNA (miRNA) strands were isolated and
analysed as biomarkers of physiological function. Fucoidan ingestion was found to affect
53 miRNAs. Fifteen were upregulated and 38 downregulated. Only one upregulated and
five downregulated miRNAs were common to both the placebo and fucoidan groups. The
pathways and processes affected by the identified miRNAs are associated with cell surface
receptor signalling, the enhancement of brain-derived neurotrophic factor, epidermal
growth factor receptor, insulin receptors, and the associated MAPK downstream signalling.
Ikeda-Ohtsubo et al. [348] evaluated the in vivo modulatory effects of fucoidan on the
gut microbiota in an animal model. Fucoidan (>95% pure, MW 49.8 kDa) was extracted
from Cladosiphon okamuranus (Okinawa mozuku) harvested in Japan. Adult zebrafish
had their food supplemented (1:1) with fucoidan for 3 weeks. The presence of pro- and
anti-inflammatory cytokines was determined by quantitative (q)PCR. Then, 16S rRNA
sequencing was used to analyse changes in the microbiota. There was a significant decrease
in expression levels of the pro-inflammatory cytokine IL-1β in the fucoidan-fed zebrafish
compared to the control. In terms of beneficial changes to the microbiota, fucoidan feeding
significantly enhanced the diversity and composition of intestinal bacterial. Bacteria of the
families Rhizobiaceae (genus Shinella) and Comamonadaceae (genus unclassified) became
dominant at the expense of E. coli-related Enterobacteriaceae. Intestinal Enterobacteriaceae
have been reported to have pro-inflammatory effects [349]. The reduction in Enterobacteri-
aceae after fucoidan supplementation may have been responsible for the downregulation
of the pro-inflammatory cytokine IL-1β. This illustrates the potential modulatory role of
seaweed polysaccharides in the diet–microbiota–host interplay.
Fucoidan extracted from Japanese Okinawa mozuku was also shown to be bioaccessi-
ble to rats fed 2% fucoidan-supplemented food for 8 weeks [350]. Immunohistochemical
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staining revealed that fucoidan had been absorbed across the intestinal epithelium and
taken up by intestinal macrophages and hepatic Kupffer cells. The same research group
went on to investigate factors concerning the absorption of the Okinawa mozuku-derived
fucoidan in a cross-sectional human study (n = 396) by Kadena et al. [351]. Okinawa
mozuku is a species of brown seaweed endemic to a small group of islands south of the
Japanese mainland called the Okinawa prefecture or region. Of the study population,
68% were native to Okinawa, while 32% were from other regions of Japan. Participants
(227 male, 169 female, age 20 to >70 years-old) were administered a drink of 3.75 g mozuku
extract (containing 3 g pure fucoidan) in 200 mL purified water. The fucoidan had an
average MW of 73.4 kDa and a composition of 51.2% L-fucose, 14.4% uronic acid, and 18.8%
sulphate. Participants refrained from consuming seaweed or fucoidan supplements the day
before and throughout the day of trial. Urine samples were collected before administration
and 3, 6, and 9 h after. The presence of fucoidan was measured using a purpose-designed
ELISA [352]. The assay antibody was specific to fucoidan and did not react with other
sulphated polysaccharides. Fucoidan concentration was expressed as a corrected urinary
creatinine value (µg/gCr) as fucoidan was calculated to be equivalent to one eighth of
urinary excreted creatinine.
The results showed that intestinal absorption of Okinawa mozuku-derived fucoidan
occurred in 97% of study participants (385 of 396). There was a highly significant difference
(p < 0.01) in fucoidan absorption in native Okinawa participants compared to those from
other regions. Eight of the 11 participants who did not excrete fucoidan lived outside
Okinawa. After 9 h, the total mean urinary fucoidan content of native Okinawa participants
(332.3 µg/gCr) was 38.4% greater (p < 0.01) than those from other regions (240.1 µg/gCr).
Of the group, 87.5% that excreted the highest levels fucoidan (>1200 µg/gCr) were native to
Okinawa. By age bracket, participants in their 40 s had the greatest mean urinary fucoidan
value (392.8 µg/gCr). The authors hypothesised that the gut bacteria of native Okinawa
participants may have acquired genes from marine bacteria that produce the digestive
enzyme fucoidanase. This horizontal transfer of genes from ocean-dwelling bacteria that
normally colonise and feed on seaweed has previously been reported in populations that
have consumed seaweed for thousands of years [353–357].
2.7.6. Bioaccessibilty of Seaweed Polyphenols
Human clinical studies on the bioaccessibility of seaweed polyphenols are limited to
brown species, and phlorotannins in particular. Table 6 summarises the polyphenol used
in each study and the impact of digestion on their bioaccessibilty.
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Table 6. Bioaccessibility of seaweed polyphenols.
Seaweed Polyphenol Extraction Method Study Type Observed Effects Ref.




fraction (>10 kDa) by tangential
flow ultrafiltration. Combined as
CE (58%) and HMW (42%)
(i) In vitro gastrointestinal enzymatic
digestion, colonic fermentation, and
dialysis to simulate absorption into the
bloodstream.
(ii) Cross-sectional human clinical trial
(12 male, 12 female, healthy
18–65 years-old) (one capsule 101.89 mg
phlorotannins). Blood and urine
collected (0 to 24 h).
Phlorotannin metabolites
detected in 15 of
24 participants after 24 h
(total phlorotannins ranged
from 0.011–7.76 µg/mL in
blood plasma and from
0.15–33.52 µg/mL in urine).
[206]
*** A. nodosum Phlorotannins
Ethanol CE extract and HMW
fraction (>10 kDa) by tangential
flow ultrafiltration. Combined as
CE (57%) and HMW (43%)
24 week crossover study (8 weeks,
100 mg phlorotannin/d, or placebo
capsule) (39 men, 41 women, mean BMI
30.2, mean age 42.7 years-old), 8 weeks
washout phase, then repeat 8 weeks
intervention or placebo treatment.
Plasma and urine collected before/after
each phase (0, 8, 16 and 24 weeks).
Polyphenol metabolites
(0.5–11.8 mg/day total
polyphenols) detected in 36
of 78 participants.
[358]
* = in vitro studies; *** = human dietary intervention studies.
Mar. Drugs 2021, 19, 358 32 of 50
These studies, along with others that have assessed the bioaccessibilty of polyphenols
from terrestrial plants, have a commonality in that oral bioaccessibilty of polyphenols in
some individuals is poor. There are a number of reasons for this, such as host-related
factors. These can be systemic factors including age, gender, genetics, and existing health
disorders; or intestinal factors, such as gastric enzyme activity, intestinal transit time, and
gut microflora composition intestinal factors such as gastric enzyme activity, intestinal
transit time, and gut microflora composition [359]. The food matrix in which polyphenols
are consumed and interactions with macronutrients impact bioaccessibility. In the digestive
tract, the amine group of proteins can form irreversible covalent bonds with the carboxylic
group of polyphenols [360], which interferes with the ability of digestive enzymes to
catabolise them. Since enzymes are proteins, polyphenols also interact with their amine
groups, further inhibiting digestion. [361,362]. The capacity for polyphenols to bind with
proteins increases with their molecular weight. Some seaweed polyphenols, such as
phlorotannins, have a MW of up to 100 kDa [363], making them suitable candidates for
multiple protein-polyphenol interactions.
Lipids have been shown to enhance polyphenol bioaccessibilty. Hydrophobic inter-
actions between lipids and polyphenols have a protective effect and increase the stability
of polyphenols during digestion [364]. Complexing with lipids can also increase the accu-
mulation of polyphenols in the liver, which acts as a slow-release reservoir that prolongs
their residence time in the blood [365]. Polysaccharides, in the form of dietary fibre, can
bind with polyphenols. The hydroxyl groups of polyphenols form hydrogen bonds with
the oxygen atoms of polysaccharide glycosidic linkages [366] or covalent bonds, such as
esters [367]. While this reduces the ability of gastric enzymes to make them bioaccessible
in the upper gastrointestinal tract, polyphenols can be released from their non-digestible
polysaccharide complex in the colon through the action of gut microbial digestive en-
zymes [368]. In fact, polysaccharides such as alginate have been used to encapsulate
polyphenols, delaying their release until they reach the colon [369].
Despite their low oral bioaccessibility, the biological activity of polyphenols is gen-
erally found to be high, leading to a low bioaccessibility/high bioactivity paradox. This
is most likely due to the biotransformation of polyphenols in the liver and enterocytes
mediated by phase I cytochrome P450 enzymes and phase II conjugation enzymes (uri-
dine 5’-diphospho-glucuronosyltransferase and sulphotransferase) [343]. Phase I and
II biotransformation is a detoxification system that modifies compounds that the body
perceives as xenobiotics for easier excretion via urine, faeces, and bile [370]. This biotrans-
formation results in conjugated compounds with different polarity, MW, ionic form, and
greater intrinsic biological effects than their parent compounds [371,372]. After compounds
such as polyphenols are conjugated, they re-enter the gastrointestinal tract in bile via
enterohepatic recirculation [373]. Gut bacterial enzymes, particularly β-glucuronidase,
can metabolise many of these polyphenol conjugates, further modifying their chemical
structure, bioactivity, and bioavailability [341]. This enterohepatic recycling prolongs the
presence of polyphenols within the body. Therefore, the limited oral bioaccessibilty of
seaweed polyphenols does not determine their ultimate bioactivity. The biotransformation
of native polyphenols through the action of digestive enzymes and microbial fermentation
produces metabolites with disparate bioaccessibilty and bioactivity.
2.7.7. Bioaccessibility of Seaweed Peptides
There is a dearth of literature on the in vivo bioaccessibility of seaweed-derived pep-
tides in human studies; however, some in vivo studies have reported the effect of digestion
on their bioactivity in animal models or in vitro. Table 7 summarises the peptide used in
each study and the impact of digestion on their bioactivity.
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Table 7. Bioactivity of seaweed peptides.







In vivo study in spontaneously
hypertensive rats.
(a) Single oral administration of each
dipeptide (50 mg/kg BM)
(b) Continuous administration for
7 days (10 mg/day/kg BM)
(a) All dipeptides decreased (p < 0.05) blood pressure after single
oral dose:
i. Tyr-His decreased 50 mm Hg after 3 h
ii. Lys-Tyr decreased 45 mm Hg after 6 h
iii. Phe-Tyr decreased 46 mm Hg after 3 h
iv. IleTyr decreased Hg 33 mm Hg after 3 h
(b) After 7 days continuous oral administration blood pressure
was lowered (all p < 0.05 compared to pre-adminstraton):
i. Tyr-His decreased 34 mm Hg
ii. Lys-Tyr decreased 26 mm Hg
iii. Phe-Tyr decreased 34 mm Hg
iv. IleTyr decreased 25 mm Hg
Hypotensive effect of all four dipeptides lasted 3–8 weeks after
ceasing continuous administration.
[374]












(a) In vitro ACE-I inhibitory activity
digestion stability study with
pepsin, trypsin and
chymotrypsin.
(b) In vivo study in spontaneously
hypertensive rats. Single oral
administration of each dipeptide
(1 mg/kg BM).
(a) No loss in ACE-I inhibitory activity post in vitro
digestion.IC50 values:
(i) Ile-Trp 1.5 µM
(ii) Val-Trp 3.3 µM
(iii) Ile-Tyr 6.1 µM
(iv) Ala-Trp 18.8 µM
(v) Leu-Trp 23.6 µM
(vi) Val-Tyr 35.2 µM
(vii) Phe-Tyr 42.3 µM
(b) In vivo antihypertensive effect in spontaneously hypertensive
rats (single oral dose, all 1 mg/kg of BW). Blood pressure
decreases (pre-administration vs. 9h post):
(i) Val-Tyr (228.2 ± 3.4 vs. 206.7 ± 9.5 mmHg) (p < 0.05)
(ii) Ile-Tyr (205.6 ± 5.2 vs. 184.3 ± 4.5 mmHg) (p < 0.05)
(iii) Phe-Tyr (208.7 ± 4.4 vs. 193.0 ± 5.1 (p < 0.01)
(iv) Ile-Trp (213.3 ± 3.4 vs. 199.5 ± 5.9) (p < 0.05)
Captopril control (238.7 ± 6.9 vs. 224.9 ± 4.1 (p < 0.05)
[229]
* = in vitro studies; ** = in vivo animal studies.
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Despite the lack of human clinical data on the bioavailability of seaweed peptides,
in vivo animal trials and in vitro simulated gastrointestinal digestion studies provide rele-
vant information on the ability of bioactive peptides, sometimes termed cryptides, to retain
their efficacy after transit through the mammalian gut [375,376].
3. Conclusions
The aetiology of many leading global chronic disorders such as inflammatory disease,
immunodeficiency, metabolic syndrome and cancer has been linked to dysbiosis of the gut.
In vitro, animal, and human studies collated in this review show that the consumption of
seaweed components may have the potential to beneficially modulate the microbiota of the
mammalian gut. Seaweed polysaccharides such as fucoidan, laminarin, alginate, ulvan and
porphyran have shown particular efficacy as modulators of the gut by acting as prebiotics,
which increase gut bacterial numbers and the production of short chain fatty acids. There
are, however, many factors that can reduce the bioaccessibility and bioavailability of
seaweed components. These include antagonistic or synergistic interactions with other
food components; physiochemical digestibility parameters such as solubility, polarity,
molecular weight, surrounding food matrix; and the impact of first-pass metabolism.
However, the low bioavailability of some seaweed components can be modified by gastric,
enterohepatic, and bacterial biotransformation resulting in compounds with enhanced
bioactivity. Another factor that affects bioaccessibility and bioavailability is the composition
of each individual’s gut microbiota, which varies broadly. This may lead to the absence of
certain bacterial families required for the metabolism of seaweed components. This can be
augmented by introducing bacterial strains capable of digesting them. There is a dearth
of data available in the literature on human dietary intervention studies with seaweed
polysaccharides, polyphenols and peptides. Although in vitro studies and in vivo animal
trials are an indication of the prebiotic potential of seaweed components, they are not fully
representative of how the component will be metabolised in humans. Further randomised
controlled clinical trials are required in large human cohorts, with measureable endpoints,
to validate any putative health effects observed in animal models, simulated digestion
models, or in vitro. With the practice of mariculture becoming more widespread globally,
seaweeds represent a sustainable source of bioactive compounds with potential to be used
as modulators of the gut microbiota.
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for the extraction of marine brown algal polysaccharides. Mar. Drugs 2020, 18, 168. [CrossRef]
12. Hao, T. Research advances on the chemical structures and medicinal values of seaweed polysaccharides. J. Anhui Agric. Sci. 2018,
2018, 14. Available online: http://en.cnki.com.cn/Article_en/CJFDTotal-AHNY201810014.htm (accessed on 11 May 2020).
13. Wijesinghe, W.A.J.P.; Jeon, Y.-J. Biological activities and potential cosmeceutical applications of bioactive components from brown
seaweeds: A review. Phytochem. Rev. 2011, 10, 431–443. [CrossRef]
14. Salehi, B.; Sharifi-Rad, J.; Seca, A.M.L.; Pinto, D.C.G.A.; Michalak, I.; Trincone, A.; Mishra, A.P.; Nigam, M.; Zam, W.; Martins, N.
Current trends on seaweeds: Looking at chemical composition, phytopharmacology, and cosmetic applications. Molecules 2019,
24, 4182. [CrossRef] [PubMed]
15. Rosa, G.P.; Tavares, W.R.; Sousa, P.M.C.; Pagès, A.K.; Seca, A.M.L.; Pinto, D.C.G.A. Seaweed secondary metabolites with beneficial
health effects: An overview of successes in in vivo studies and clinical trials. Mar. Drugs 2019, 18, 8. [CrossRef]
16. Marzullo, P.; Di Renzo, L.; Pugliese, G.; De Siena, M.; Barrea, L.; Muscogiuri, G.; Colao, A.; Savastano, S. From obesity through
gut microbiota to cardiovascular diseases: A dangerous journey. Int. J. Obes. Suppl. 2020, 10, 35–49. [CrossRef] [PubMed]
17. Barko, P.C.; McMichael, M.A.; Swanson, K.S.; Williams, D.A. The gastrointestinal microbiome: A Review. J. Vet. Intern. Med. 2018,
32, 9–25. [CrossRef] [PubMed]
18. Milani, C.; Duranti, S.; Bottacini, F.; Casey, E.; Turroni, F.; Mahony, J.; Belzer, C.; Delgado Palacio, S.; Arboleya Montes, S.;
Mancabelli, L.; et al. The first microbial colonizers of the human gut: Composition, activities, and health implications of the infant
gut microbiota. Microbiol. Mol. Biol. Rev. 2017, 81, e00036-17. [CrossRef] [PubMed]
19. Rinninella, E.; Raoul, P.; Cintoni, M. What is the healthy gut microbiota composition? A changing ecosystem across age,
environment, diet, and diseases. Microorganisms 2019, 7, 14. [CrossRef]
20. Flint, H.J. Chapter 6-Variability and stability of the human gut microbiome. In Why Gut Microbes Matter: Understanding Our
Microbiome; Flint, H., Ed.; Springer Nature: Cham, Switzerland, 2020; pp. 63–79. [CrossRef]
21. Arumugam, M.; Raes, J.; Pelletier, E.; Le Paslier, D.; Yamada, T.; Mende, D.R.; Fernandes, G.R.; Tap, J.; Bruls, T.; Batto, J.-M.; et al.
Enterotypes of the human gut microbiome. Nature 2011, 473, 174–180. [CrossRef] [PubMed]
22. Özgün, C.O.U.; Knut, R.; Dzung, B.D. Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microb. Ecol. Health
Dis. 2017, 28, 1348886. [CrossRef]
23. Busnelli, M.; Manzini, S. The gut microbiota affects host pathophysiology as an endocrine organ: A focus on cardiovascular
disease. Nutrients 2020, 12, 79. [CrossRef]
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